BARIATRIC SURGERY	CARDIOLOGY	CARDIOTHORACIC SURGERIES இருதய நோய் அறுவை சிகிச்சை	DERMATOLOGY	E N T காது மூக்கு தொண்டை சிகிச்சை	ENDOCRINE SURGERY	ENDOCRINOLOGY உட்சுரப்பி சிகிச்சை
GASTROENTEROLOGY	GENERAL MEDICINE பொது மருத்துவ சிகிச்சை	GENERAL SURGERY பொது அறுவை சிகிச்சை	GENITOURINARY SURGERY இருபாலார் சிறுநீரக நோய் சிகிச்சை	GYNAECOLOGY OBSTETRIC SURGERY இரத்தவகை சிகிச்சை	HEMATOLOGY இரத்தவகை சிகிச்சை	HEPATOLOGY கல்லீரல் நோய் சிகிச்சை
INFECTIOUS DISEASES - GENERAL MEDICINE	INTERVENTIONAL CARDIOLOGY இடையீடு இருதயவியல்	INTERVENTIONAL RADIOLOGY இடையீடு கதிர்வீச்சு இருதய சிகிச்சை	MEDICAL GASTROENTROLOGY	MEDICAL ONCOLOGY புற்றுநோய் மருத்துவ சிகிச்சை	NEONATOLOGY பச்சிளம் குழந்தைகள் சிகிச்சை	NEPHROLOGY
NEUROLOGY நரம்பியல் சிகிச்சை	NEUROSURGERY நரம்பியல் அறுவை சிகிச்சை	OFMS வாய் வழி மற்றும் தாடை அறுவை சிகிச்சை	OPHTHALMOLOGY SURGERIES கண் நோய் அறுவை சிகிச்சை	ORTHOPEDICS எலும்பியல் காயம்	PAEDIATRIC INTENSIVE CARE குழந்தைகளுக்கான தீவிர சிகிச்சை	PAEDIATRIC SURGERIES குழந்தைகளுக்கான அறுவை சிகிச்சை
PAEDIATRICS குழந்தை மருத்துவம்	PAIN & PALLIATION கடைநிலை மருத்துவம்	PLASTIC SURGERY ஒட்டுறுப்பு அறுவை சிகிச்சை	POLYTRAUMA	PSYCHIATRY மனநல மருத்துவம்	PULMONLOGY நுரையீரல் நோய்	RADIATION ONCOLOGY கதிர்வீச்சு புற்றுநோய்
REHABILITATION	RHEUMATOLOGY முடக்கு வாதம்	SPINE	SURGICAL GASTRO ENTEROLOGY இரையகக் குடலியவியல்	SURGICAL ONCOLOGY புற்றுநோய் அறுவைசிகிச்சை	THORACIC MEDICINE	VASCULAR SURGERIES நாளஞ்சார் அறுவை சிகிச்சைகள்

Package Name	Category	A1	A2	A3	A4	A5	A6	S1	S2
CMU0106 : BREAST CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -a : BREAST CANCER - COMBINED REGIMEN AC & T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -a-I : BREAST CANCER - DOSE DENSE AC (ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; (DAY 1 - DOXORUBICIN 60MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV) ; REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES; FOLLOWED BY PACLITAXEL FOR 4 CYCLES	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0106 -a-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU0106 -a-III : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU0106 -a-IV : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 80MG/M2) REPEAT CYCLE - WEEKLY FOR 12 CYCLES	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0106 -b : BREAST CANCER - TC (DOECTAXEL & CYCLOPHOSPHAMIDE) ; DAY 1 - DOCETAXEL 75MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CMU0106 -c : BREAST CANCER - CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/FLUOROURACIL) - (INCLUDES DAY 1 & DAY 8) ; DAYS 1-14 - CYCLOPHOSPHAMIDE 100MG/M2 ORALLY ; DAYS 1 AND 8 - METHOTREXATE 40MG/M2 IV ; DAYS 1 AND 8 - 5-FLUOROURACIL 600MG/M2 IV. ; REPEAT CYCLE - EVERY 28 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CMU0106 -d : BREAST CANCER - EC (EPIRUBICIN/CYCLOPHOSPHAMIDE) ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 830MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 8 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CMU0106 -e : BREAST CANCER - FEC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -e-I : BREAST CANCER - FEC/CEF FOLLOWED BY T (FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY DOCETAXEL OR FOLLOWED BY WEEKLY PACLITAXEL) ; DAY 1 - 5-FLUOROURACIL 500MG/M2 IV ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CMU0106 -e-II : BREAST CANCER - DOCETAXEL - (PRECEEDED BY FEC/CEF ) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0106 -e-III : BREAST CANCER - PACLITAXEL - WEEKLY - (PRECEEDED BY FEC/CEF ) ; PACLITAXEL 100MG/M2 IV ; REPEAT CYCLE - ONCE WEEKLY FOR 8 WEEKS	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0106 -f : BREAST CANCER - FAC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -f-I : BREAST CANCER - FAC FOLLOWED BY T (FLUOROURACIL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY WEEKLY PACLITAXEL ; 5-FLUOROURACIL 500MG/M2 IV DAYS 1 AND 8 OR 1 AND 4 - ; DAY 1 - DOXORUBICIN 50MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CMU0106 -f-II : BREAST CANCER - PACLITAXEL - WEEKLY - PRECEEDED BY FAC ; PACLITAXEL 80MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0106 -g : BREAST CANCER - TAC (DOCETAXEL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CMU0106 -h : BREAST CANCER - AC FOLLOWED BY T + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -h-I : BREAST CANCER - AC - FOLLOWED BY PACLITAXEL + TRASTUZUMAB +/- PERTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLE	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0106 -h-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY AC) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0106 -h-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH PACLITAXEL CYCLE 1, 4, 7, 10 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -h-IV : BREAST CANCER - TRASTUZUMAB 4MG (FOLLOWED BY TRASTUZUMAB 2MG SUBSEQUENT WEEKS) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -h-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY TILL ONE YEAR FROM DAY 1 OF AC. ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12 AND STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0106 -i : BREAST CANCER - TCH	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -i-I : BREAST CANCER - TC (DOCETAXEL/CARBOPLATIN) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CARBOPLATIN AUC 6MG PER MIN/ML IV. ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0106 -i-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH TC CYCLE 1 TO 6 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 18 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -i-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH TC CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -i-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES - WEEKLY) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 17 WEEEKS MAY OVERLAP WITH TC CYCLES 2 - 6. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0106 -j : BREAST CANCER - AC FOLLOWED BY DOCETAXEL + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -j-I : BREAST CANCER - AC - FOLLOWED BY DOCETAXEL + TRASTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0106 -j-II : BREAST CANCER - DOCETAXEL (PRECEEDED BY AC) + TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
CMU0106 -j-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS TILL 1 YEAR ; (TO BE APPROVED WITH DOCETAXEL CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) OR FROM 13 TH WEEK AFTER COMPLETION OF 12 WEEKS OF WEEKLY TRASTUZUMAB - UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -j-IV : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -j-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0106 -k : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -k-I : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE - WITH TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CMU0106 -k-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; (TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -k-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -k-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0106 -L : BREAST CANCER - PACLITAXEL + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0106 -L-I : BREAST CANCER - PACLITAXEL - (WITH TRASTUZUMAB) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0106 -L-II : BREAST CANCER - TRASTUZUMAB (6MG) ; TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS ; (TO BE APPROVED AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -L-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
CMU0106 -L-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12. MAY BE APPROVED AS STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK OR TRASTUZUMAB 6MG PACKAGE MAY BE USED ONCE EVERY 21 DAYS UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0106 -N : BREAST CANCER - TAMOXIFEN	MEDICAL ONCOLOGY	100	100	100	100	100	100	100	100
CMU0106 -O : BREAST CANCER - AROMATASE INHIBITORS	MEDICAL ONCOLOGY	1100	1100	1100	1100	1100	1100	1100	1100
CMU0106 -P : BREAST CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CMU0107 : BLADDER CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0107 -a-I : BLADDER CANCER - DDMVAC ; DAY 1 - METHOTREXATE 30MG/M2 IV; DAY 2 - VINBLASTINE 3MG/M2 IV, DOXORUBICIN 30MG/M2 IV, CISPLATIN 70MG/M2 IV; ; REPEAT EVERY 2 WEEKS FOR 3-4 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0107 -a-II : BLADDER CANCER - GEMCITABINE + CISPLATIN ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV; DAY 2 - CISPLATIN 70MG/M2. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CMU0107 -a-III : BLADDER CANCER - CISPLATIN + METHOTREXATE + VINBLASTINE (CMV) ; DAY 1 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV; DAY 2 - CISPLATIN 100MG/M2 IV, LEUCOVORIN 15MG ORAL OR IV EVERY 6 HOURS FOR 4 DOSES; DAY 8 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV DAY 9 - LEUCOVORIN 15MG ORAL EVERY 6 HOURS FOR 4 DOSES ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CMU0107 -a-IV : BLADDER CANCER - RADIOSENSITIZING - CISPLATINC + 5-FU ; DAYS 1, 2, 3, 15, 16, AND 17 - IV HYDRATION AT A RATE OF 500ML/HOUR; FOLLOWED BY 5-FU 400MG/M2 IV PUSH; FOLLOWED BY CISPLATIN 15MG/M2 IV OVER 1 HOUR AS INDUCTION AND CONSOLIDATION THERAPY	MEDICAL ONCOLOGY	10300	10300	10300	10300	10300	10300	10300	10300
CMU0107 -a-V : BLADDER CANCER -RADIOSENSITIZING - CISPLATIN + PACLITAXEL ; DAYS 1, 8, AND 15 - PACLITAXEL 50MG/M2 ; DAY 1-3, 8-10, 15-17 - CISPLATIN 15MG/M2; FOLLOWED BY TWICE-DAILY RADIOTHERAPY FOR 8 DAYS	MEDICAL ONCOLOGY	19300	19300	19300	19300	19300	19300	19300	19300
CMU0107 -a-VI : BLADDER CANCER -RADIOSENSITIZING - 5-FU + MITOMYCIN32 ; DAY 1 OF RADIOTHERAPY - MITOMYCIN 12MG/M2 IV BOLUS, PLUS ; WEEK 1 (FRACTIONS 1-5) AND WEEK 4 (FRACTIONS 16-20) OF RADIOTHERAPY - 5-FU 500MG/M2 CONTINUOUS IV INFUSION (10 DAYS TOTAL)	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
CMU0107 -c : BLADDER CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0108 : LUNG CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0108 -i : LUNG CANCER - MESOTHELIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0108 -i-a : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CISPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CISPLATIN 75MG/M2 ; REPEAT EVERY 21 DAYS UP TO 12 CYCLES.	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
CMU0108 -i-b : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CARBOPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CARBOPLATIN AUC 5MG/MIN/ML IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 9 CYCLES.	MEDICAL ONCOLOGY	17300	17300	17300	17300	17300	17300	17300	17300
CMU0108 -i-c : LUNG CANCER - MESOTHELIOMA - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 80-100MG/M2 IV ; DAYS 1, 8, AND 15 - GEMCITABINE 1000-1250MG/M2 IV ; REPEAT EVERY 21 - 28 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0108 -i-d : LUNG CANCER - MESOTHELIOMA - VINORELBINE ; VINORELBINE 25-30MG/M2 (MAX 60MG) IV ; REPEAT EVERY WEEK FOR 12 WEEKS.	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
CMU0108 -i-e : LUNG CANCER - MESOTHELIOMA - PEMETREXED ; DAY 1 - PEMETREXED 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR 4 CYCLES (IF FIRST LINE) OR REPEAT EVERY 21 DAYS FOR 8 CYCLES (IF SECOND LINE)	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
CMU0108 -i-f : LUNG CANCER - MESOTHELIOMA - GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 28 DAYS FOR A MAX OF 10 CYCLES.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0108 -ii : LUNG CANCER - NSCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0108 -ii-a : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (I) ; DAYS 1 AND 8 - CISPLATIN 50MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 25MG/M2 IV ; (OR) ; DAY 1 - CISPLATIN 100MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 30MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	35300	35300	35300	35300	35300	35300	35300	35300
CMU0108 -ii-b : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (II) ; DAY 1 - CISPLATIN 75-80MG/M2 ; DAYS 1 AND 8 - VINORELBINE 25-30MG/M2. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	18800	18800	18800	18800	18800	18800	18800	18800
CMU0108 -ii-c : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
CMU0108 -ii-d : LUNG CANCER - NSCLC - CISPLATIN & DOCETAXEL ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
CMU0108 -ii-e : LUNG CANCER - NSCLC - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 1 AND 8 - GEMCITABINE 1, 250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	6400	6400	6400	6400	6400	6400	6400	6400
CMU0108 -ii-f : LUNG CANCER - NSCLC - PEMETREXED + CISPLATIN (FOR NON SQUAMOUS CELL CA) ; DAY 1 - CISPLATIN 75MG/M2 IV, PEMETREXED 500MG/M2 IV. ; REPEAT EVERY - 21 DAYS FOR 4 CYCLES.	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
CMU0108 -ii-g : LUNG CANCER - NSCLC - PACLITAXEL/CARBOPLATIN ; DAY 1 - PACLITAXEL 200MG/M2 IV, CARBOPLATIN AUC 6MG PER MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CMU0108 -ii-h : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAYS 1, 8, 29 AND 36 - CISPLATIN 50MG/M2 IV ; DAYS 1-5 AND 29-33 - ETOPOSIDE 50MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY 1.8GY/DAY FOR 5 DAYS/WEEK (TOTAL DOSE, 61GY).	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CMU0108 -ii-i : LUNG CANCER - NSCLC - CISPLATIN & VINBLASTINE ; DAYS 1 AND 29 - CISPLATIN 100MG/M2 IV ; DAYS 1, 8, 15, 22 AND 29 - VINBLASTINE 5MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY).	MEDICAL ONCOLOGY	8600	8600	8600	8600	8600	8600	8600	8600
CMU0108 -iii : LUNG CANCER - SCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0108 -iii-a : LUNG CANCER - SCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 60MG/M2 IV, DAYS 1-3 - ETOPOSIDE 120MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR AT LEAST 4 CYCLES. ;(OR) ; DAY 1 - CISPLATIN 80MG/M2 IV, DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4-6 CYCLES.	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
CMU0108 -iii-b : LUNG CANCER - SCLC - CARBOPLATIN & ETOPOSIDE ; DAY 1 - CARBOPLATIN AUC 5-6MG PER MIN/ML IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS OR 28 DAYS FOR 4 - 6 CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0108 -iii-c : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CMU0108 -iii-d : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 AND 8 - CISPLATIN 30MG/M2 IV, IRINOTECAN 65MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4-6 CYCLES.	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CMU0108 -iii-e : LUNG CANCER - SCLC - CARBOPLATIN & IRINOTECAN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 50MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
CMU0108 -ii-j : LUNG CANCER - NSCLC - CARBOPLATIN + PEMETREXED ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	17300	17300	17300	17300	17300	17300	17300	17300
CMU0108 -ii-k : LUNG CANCER - NSCLC - CISPLATIN + PEMETREXED ; DAY 1 - CISPLATIN 75 MG/M2 IV. ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	15700	15700	15700	15700	15700	15700	15700	15700
CMU0108 -ii-l : LUNG CANCER - NSCLC - PACLITAXEL + CARBOPLATIN ; PACLITAXEL 45MG/M2 IV + CARBOPLATIN AUC 2MG PER MIN/ML IV ; WITH CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY) ; REPEAT WEEKLY FOR 6 WEEKS	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU0109 : OESOPHAGEAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0109 -i : ESOPHAGEAL CANCER - NEO ADJUVANT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0109 -i-a : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV + CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU0109 -i-b : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV.	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
CMU0109 -i-c : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 AND DAYS 22-26 - 5-FU 800 MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0109 -i-d : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL + OXALIPLATIN + LEUCOVORIN ; DAY 1 - OXALIPLATIN 85MG/M2, LEUCOVORIN 200MG/M2 AND 5-FU 400MG/M2 BOLUS, WITH 1, 600MG/M2 INFUSION; ; REPEAT EVERY 14 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CMU0109 -i-e : ESOPHAGEAL CANCER - NEO ADJUVANT - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
CMU0109 -i-f : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
CMU0109 -i-g : ESOPHAGEAL CANCER - NEO ADJUVANT - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS.	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0109 -i-h : ESOPHAGEAL CANCER - NEO ADJUVANT - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV, CISPLATIN 30MG/M2 IV.	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
CMU0109 -i-i : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV INFUSION. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0109 -ii : ESOPHAGEAL CANCER - PERI-OPERATIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0109 -ii-a : ESOPHAGEAL CANCER - PERI-OPERATIVE - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV CONTINUOUS INFUSION ONCE DAILY; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
CMU0109 -ii-b : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	19700	19700	19700	19700	19700	19700	19700	19700
CMU0109 -ii-c : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOC (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
CMU0109 -ii-d : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-4 CYCLES	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
CMU0109 -ii-e : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLESCYCLED EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0109 -iii : ESOPHAGEAL CANCER - POST-OPERATIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0109 -iii-a : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (I) ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV, FOLLOWED BY 4 WEEKS BREAK AND CCRT ; RT DAYS 1-4 AND 23-25 - 5-FU 400MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV.	MEDICAL ONCOLOGY	26700	26700	26700	26700	26700	26700	26700	26700
CMU0109 -iii-b : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 200MG/M2 IV, 5-FU 400MG/M2 IV PUSH AND 5-FU 600MG/M2 INFUSION	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
CMU0109 -iii-c : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY; ; REPEAT EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CMU0109 -iii-d : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY, ; ONCE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CMU0109 -iii-e : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACILDAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS DAILY, ; ONCE WEEKLY FOR 5 WEEKS.ONCE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0109 -i-j : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0109 -iv : ESOPHAGEAL CANCER - DEFINITIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0109 -iv-a : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
CMU0109 -iv-b : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0109 -iv-c : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY CONTINUOUS IV INFUSION.	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
CMU0109 -iv-d : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CMU0109 -iv-e : ESOPHAGEAL CANCER - DEFINITIVE - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0109 -iv-f : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV AND CARBOPLATIN 2MG/MIN/ML IV ; REPEAT WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU0109 -iv-g : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (I) ; DAYS 1 AND 22 - DOCETAXEL 60MG/M2 IV ; DAYS 1 AND 22 - CISPLATIN 60-80MG/M2 IV GIVEN FOR 1 CYCLE	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0109 -iv-h : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (II) ; DAY 1 - DOCETAXEL 20-30MG/M2 IV ; DAY 1 - CISPLATIN 20-30MG/M2 IV ; REPEAT WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0109 -iv-i : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH PACLITAXEL ; DAYS 1, 8, 15, AND 22 - PACLITAXEL 60MG/M2 IV ; DAY 1 - CISPLATIN 75MG/M2 IV GIVEN FOR 1 CYCLE.	MEDICAL ONCOLOGY	13800	13800	13800	13800	13800	13800	13800	13800
CMU0109 -iv-j : ESOPHAGEAL CANCER - DEFINITIVE - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV ; DAYS 1, 8, 22, AND 29 - CISPLATIN 30MG/M2 IV.	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
CMU0109 -iv-k : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0109 -iv-l : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 PO TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0109 -v : ESOPHAGEAL CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0110 : GASTRIC CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0110 -i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0110 -i-a : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV, CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU0110 -i-b : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1000MG/M2/DAY IV	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
CMU0110 -i-c : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV ONCE DAILY, 5-FU 800MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 2 CYCLES.	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0110 -i-d : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (I)DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV.	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
CMU0110 -i-e : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (II)DAY 1 - OXALIPLATIN 85MG/M2 AND LEUCOVORIN 400MG/M2 FOLLOWED BY 5-FU 400MG/M2 BOLUS, THEN 800MG/M2 24-HOUR CONTINUOUS INFUSION OVER DAYS 1 AND 2; THE FIRST 3 CYCLES WERE DELIVERED DURING RADIOTHERAPY (RT), THE OTHER 3 AFTER RT; 6 BIMONTHLY (14 DAYS) CYCLES.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0110 -i-f : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CMU0110 -i-g : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0110 -i-h : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45-50MG/M2 IV WEEKLY ; DAYS 1-5 - 5-FU 300MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0110 -ii : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0110 -i-i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CMU0110 -ii-a : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV, CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
CMU0110 -ii-b : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EOF (EPIRUBICIN/ OXALIPLATIN /FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	19300	19300	19300	19300	19300	19300	19300	19300
CMU0110 -ii-c : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EPIRUBICIN + CISPLATIN + CAPECITABINE ; DAY 1 - EPIRUBICIN 50MG/M2 IV + CISPLATIN 60MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CMU0110 -ii-d : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF MODIFICATION (EPIRUBICIN + OXALIPLATIN + CAPECITABINE) ; DAY 1 - EPIRUBICIN 50MG/M2 IV + OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELYREPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
CMU0110 -ii-e : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL & CISPLATIN ; DAY 1 - CISPLATIN 75-80MG/M2 IV ; DAYS 1-5 - 5-FU 800MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-3 CYCLES PREOPERATIVELY AND 3-4 CYCLES POSTOPERATIVELY FOR A TOTAL OF 6 CYCLES.	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
CMU0110 -iii : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0110 -iii-a : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (I) ; CYCLES 1, 3, AND 4 (BEFORE AND AFTER RADIATION) DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2/DAY IV ; REPEAT CYCLE EVERY 28 DAYS. ; CYCLE 2 (WITH RADIATION) DAYS 1-4 AND 31-33 - LEUCOVORIN 20MG/M2 IVP ; DAYS 1-4 - 5-FU 400MG/M2/DAY IVP. ; REPEAT CYCLE EVERY 35 DAYS	MEDICAL ONCOLOGY	26700	26700	26700	26700	26700	26700	26700	26700
CMU0110 -iii-b : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV AND 5-FU 1200MG/M2 INFUSION; ; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. ; REPEAT CYCLE EVERY 28 DAYSREPEAT CYCLE EVERY 28 DAYS	MEDICAL ONCOLOGY	15700	15700	15700	15700	15700	15700	15700	15700
CMU0110 -iii-c : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CMU0110 -iii-d : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY; WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CMU0110 -iii-e : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL ; DAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV; ; WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0110 -iii-f : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	4200	4200	4200	4200	4200	4200	4200	4200
CMU0110 -iii-h : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - OXALIPLATIN + CAPECITABINE ; DAY 1 - OXALIPLATIN 130MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CMU0111 : COLORECTAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0111 -i : COLORECTAL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0111 -i-a : COLORECTAL CARCINOMA - FOLFOX (STAGE - III) - (OXALIPLATIN, LEUCOVORIN, 5-FU) ; DAY 1 - OXALIPLATIN 85MG/M2 IV, LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV, FOLLOWED BY 5-FU 1, 200MG/M2/DAY IV X 2 DAYS (TOTAL 2, 400MG/M2) OVER 46-48-HOUR CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS- UPTO 12 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
CMU0111 -i-b : COLORECTAL CARCINOMA - CAPEOX (STAGE - III) (OXALIPLATIN, CAPECITABINE) ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAYS 1-14 - CAPECITABINE 1, 000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 MONTHS	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0111 -i-c : COLORECTAL CARCINOMA - FLOX (STAGE - III) (5-FU, LEUCOVORIN, OXALIPLATIN) ; 5-FU 500MG/M2 IV BOLUS WEEKLY X 6, LEUCOVORIN 500MG/M2 IV WEEKLY X 6, EACH ; OXALIPLATIN 85MG/M2 IV ON WEEKS 1, 3, AND 5 ; 8-WEEK CYCLE X 3 CYCLES ;	MEDICAL ONCOLOGY	31500	31500	31500	31500	31500	31500	31500	31500
CMU0111 -i-d : COLORECTAL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKSL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKS	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CMU0111 -i-e : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (I) ; LEUCOVORIN 500MG/M2 WEEKLY X 6 WEEKS, ; 5-FU 500MG/M2 WEEKLY X 6 WEEKS. ; REPEAT CYCLE EVERY 8 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	24900	24900	24900	24900	24900	24900	24900	24900
CMU0111 -i-f : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (II)SIMPLIFIED BIWEEKLY INFUSION. ; LEUCOVORIN 400MG/M2 IV, 5-FU BOLUS 400MG/M2 AND THEN 1, 200MG/M2/DAY X 2 DAYS (TOTAL 2, 400MG/M2 OVER 46-48 HOURS) ; REPEAT CYCLE EVERY 2 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CMU0111 -ii : COLORECTAL CARCINOMA - CONCURRENT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0111 -ii-a : COLORECTAL CARCINOMA - CONCURRENT - 5FU - WITH XRT ; DAYS 1-5 OR 1-7 - 5-FU 225MG/M2 IV ; WITH EXTERNAL BEAM RADIOTHERAPY	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0111 -ii-b : COLORECTAL CARCINOMA - CONCURRENT - FLUOROURACIL + LEUCOVORIN - WITH XRT ; DAYS 1-4 - 5-FU 400MG/M2 IV + LEUCOVORIN 20MG/M2 IV. ; REPEAT CYCLE DURING WEEKS 1 AND 5 OF XRT.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0111 -ii-c : COLORECTAL CARCINOMA - CONCURRENT - CAPECITABINE - WITH XRT ; CAPECITABINE TABLET 825MG / M2 TWICE DAILY ON DAYS 1-5 ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1400	1400	1400	1400	1400	1400	1400	1400
CMU0112 : OSTEOSARCOMA/ BONE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0112 -i-a : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - CISPLATIN + DOXORUBICIN ; DAYS 1-3 - DOXORUBICIN 25MG/M2/DAY IV, ; DAY 1 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CMU0112 -i-b-1 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - PRE OPERATIVE ; DAYS 1 AND 28 - METHOTREXATE 8G/M2 IV ; DAYS 7-9 AND 34-36 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. ; DAYS 9 AND 36 - DOXORUBICIN 60MG/M2 IV	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CMU0112 -i-b-2 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS < 90% ; DAYS 1, 48, 96, AND 144 - DOXORUBICIN 45MG/M2/DAY FOR 2 CONSECUTIVE DAYS ; DAYS 21, 69, AND 117 - METHOTREXATE 8G/M2 IV ; DAYS 27, 75, AND 123 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS.	MEDICAL ONCOLOGY	42000	42000	42000	42000	42000	42000	42000	42000
CMU0112 -i-b-3 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS > 90%POSTOPERATIVE CHEMOTHERAPY (NECROSIS	MEDICAL ONCOLOGY	62000	62000	62000	62000	62000	62000	62000	62000
CMU0112 -i-c : DOXORUBICIN + CISPLATIN + IFOSFAMIDE + HIGH-DOSE METHOTREXATE (INCLUDING SURGERY COST)	MEDICAL ONCOLOGY	117100	117100	117100	117100	117100	117100	117100	117100
CMU0112 -i-d : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - IFOSFAMIDE + CISPLATIN + EPIRUBICIN ; DAY 1 - EPIRUBICIN 90MG/M2 IV, CISPLATIN 100MG/M2 IV ; DAYS 2-4 - IFOSFAMIDE 2.0G/M2 WITH MESNA ; REPEAT CYCLE EVERY 21 DAYS. (3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY).	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
CMU0112 -ii : OTHER BONE TUMORS - CHORDROMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0112 -ii-a : OTHER BONE TUMORS - CHORDROMA - IMATINIB ; IMATINIB 800 MG ONCE DAILY	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CMU0112 -ii-b : OTHER BONE TUMORS - CHORDROMA - IMATINIB + CISPLATIN ; IMATINIB 400MG OD + CISPLATIN 25MG/M2 WEEKLY.	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CMU0112 -ii-c : OTHER BONE TUMORS - CHORDROMA - IMATINIB + SIROLIMUS ; IMATINIB 400MG OD + SIROLIMUS 2MG OD	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CMU0112 -ii-d : OTHER BONE TUMORS - CHORDROMA - ERLOTINIB ; ERLOTINIB 150MG OD	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
CMU0112 -ii-e : OTHER BONE TUMORS - CHORDROMA - SUNITINIB ; SUNITINIB 37.5MG OD	MEDICAL ONCOLOGY	29900	29900	29900	29900	29900	29900	29900	29900
CMU0112 -iii : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0112 -iii-a : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - DENOSUMAB ; DENOSUMAB 120MG SUBCUTANEOUS ON WEEK 1, 2 AND 3 OF A 4 WEEK CYCLE	MEDICAL ONCOLOGY	58800	58800	58800	58800	58800	58800	58800	58800
CMU0112 -iii-b : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - INTERFERON ALFA ; INTERFERON ALFA- 2A THRICE WEEKLY	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CMU0112 -iii-c : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - PEGINTERFERON ; PEGINTERFERON ALFA-2A 1.0MCG/KG SQ INJECTION WEEKLY.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0112 -iv : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0112 -iv-a : VAC AND IE CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0112 -iv-b : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VAIA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0112 -vi : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VIDE (VINCRISTINE + IFOSFAMIDE + DOXORUBICIN + ETOPOSIDE) ; DAY 1 - VINCRISTINE 1.4MG/M2 (MAX 2MG), ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV + IFOSFAMIDE 3MG/M2 IV + MESNA 3G/M2 + ETOPOSIDE 150MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES.	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CMU0113 : WILMS TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0113 -a : WILMS TUMOR - VINCRISTINE & ACTINOMYCIN D ; DACTINOMYCIN 45MCG/KG - WEEK - 0, 3, 6, 9, 12, 15, 18 ; VINCRISTINE 1.5 MG/M2 - WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18	MEDICAL ONCOLOGY	20400	20400	20400	20400	20400	20400	20400	20400
CMU0113 -b : WILMS TUMOR - DACTINOMYCIN, VINCRISTINE & ADRIAMYCIN ; DACTINOMYCIN 1.35 MG /M2 - WEEK - 0, 6, 12, 18, 24 ; ADRIYAMYCIN 30-45 MG /M2- WEEK - 3, 9, 15, 21 ; VINCRISTINE 2MG MAX- WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 24	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
CMU0113 -c : WILMS TUMOR - ADRIAMYCIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 3, 9, 15, 21 FOR 5 DAYS, WEEK - 6, 12, 18, 24 FOR 3 DAYS ; ADRIYAMYCIN 30-45MG /M2- WEEK -0, 6, 12, 18, 24 ; VINCRISTINE 2MG (MAX)- WEEK - 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 18, 24 ; ETOPOSIDE 100MG /M2- WEEK - 3, 9, 15, 21	MEDICAL ONCOLOGY	56400	56400	56400	56400	56400	56400	56400	56400
CMU0113 -d : WILMS TUMOR - CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 6, 15, 24 *5 DAYS / WEEK ; CARBOPLATIN 500MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *2 DAYS / WEEK ; ETOPOSIDE 100MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *5 DAYS / WEEK	MEDICAL ONCOLOGY	88700	88700	88700	88700	88700	88700	88700	88700
CMU0114 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0114 -a : HEPATOBLASTOMA- OPERABLE - PLADO - CISPLATIN + DOXORUBICIN ; CISPLATIN (PLA) (80MG/M2 / IV), DOXORUBICIN (DO) (30 MG/M2 IV ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CMU0114 -b : HEPATOBLASTOMA- OPERABLE - CISPLATIN + VINCRISTINE +5FU ; CISPLATIN (90 MG/M2), VINCRISTINE (1.5MG/M2), 5-FU(5-FLUROURACIL- 600 MG/M2) ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
CMU0115 : HEPATOCELLULAR CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0115 -a : HEPATOCELLULAR CARCINOMA - SORAFENIB ; SORAFENIB 400 MG PO BID	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CMU0116 : NEUROBLASTOMA ALL STAGES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0116 A : NEUROBLASTOMA ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
CMU0116 B : NEUROBLASTOMA ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300MG/M2 ; ADRIAMYCIN 60MG/M2 ; VINCRISTINE 1.5MG/M2	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0116 C : NEUROBLASTOMA ALL STAGES - CISPLATIN & ETOPOSIDE ; DAYS 1-5 - CISPLATIN - 20MG/M2 ; DAYS 1-5 - ETOPOSIDE - 70 MG/M2	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
CMU0116 D : NEUROBLASTOMA ALL STAGES - CARBOPLATIN & ETOPOSIDE ; DAYS 1-2 - CARBOPLATIN - 500MG/M2 ; DAYS 1-5 - ETOPOSIDE 100MG/M2	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0116 E : NEUROBLASTOMA ALL STAGES - FOR STAGE IV PALLIATIVE CHEMOTHERAPY ONLY	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
CMU0117 : RETINOBLASTOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0117 -a : RETINOBLASTOMA - MELPHALAN - INTRA-ARTERIAL ; MELPHALAN - 3-7.5MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
CMU0117 -b : RETINOBLASTOMA - CARBOPLATIN - INTRA-ARTERIAL ; CARBOPLATIN 15-30 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0117 -c : RETINOBLASTOMA - TOPOTECAN - INTRA-ARTERIAL ; TOPOTECAN 0.15-1.5 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
CMU0117 -d : RETINOBLASTOMA - METHOTREXATE - INTRA-ARTERIAL ; METHOTREXATE 6-12 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	9100	9100	9100	9100	9100	9100	9100	9100
CMU0117 -e : RETINOBLASTOMA - CARBOPLATIN - PERI OCULAR ; CARBOPLATIN 20MG/M2 - PERI OCULAR	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CMU0117 -f : RETINOBLASTOMA - TOPOTECAN - PERI OCULAR ; TOPOTECAN 0.09 - 0.27 - PERI OCULAR	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
CMU0117 -g : RETINOBLASTOMA - MELPHALAN - INTRA-VITREAL ; MELPHALAN 20-30 MCG / 0.1CC - INTRA-VITREAL	MEDICAL ONCOLOGY	300	300	300	300	300	300	300	300
CMU0117 -h : RETINOBLASTOMA - CARBOPLATIN - INTRA-VITREAL ; CARBOPLATIN 3-6MCG / 0.05CC - INTRA-VITREAL	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CMU0117 -i : RETINOBLASTOMA - METHOTREXATE - INTRA-VITREAL ; METHOTREXATE 400MCG/0.1CC - INTRA-VITREAL	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CMU0117 -j : RETINOBLASTOMA - CARBOPLATIN + ETOPOSIDE + VINCRISTINE ; CARBOPLATIN 560MG/M2 ; ETOPOSIDE 150MG/M2 ; VINCRISTINE 1.5MG/M2	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0118 : HISTIOCYTOSIS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0118 -a : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 1; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0118 -b : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 2; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0118 -c : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - CONTINUATION; PREDNISOLONE AND VINBLASTINE - CONTINUATION AFTER EITHER COURSE 1 OR BOTH 1 & 2 ; PREDNISOLONE - 5 DAYS A WEEK ORAL ; VINBLASTINE -IV ; REPEAT EVERY 3 WEEKS TILL 1 YEAR	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0119 : RHABDOMYOSARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0119 -a : RHABDOMYOSARCOMA - VAC (VINCRISTINE + DACTINOMYCIN + CYCLOPHOSPHAMIDE + MESNA ) ; DAY -1 - VINCRISTINE 1.5 MG /M2 IV (2 MG MAX), DOXORUBICIN 75 MG /M2 IV, CYCLOPHOSPHAMIDE 1200 MG /M2 IV + MESNA ; REPEAT AT 21 DAY INTERVALS FOR 4-6 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0119 -b : RHABDOMYOSARCOMA - IVA (VINCRISTINE + DACTINOMYCIN + IFOSFAMIDE + MESNA ) ; DAY 1, 2 - IFOSFAMIDE IV 3 G/M2 + MESNA ; DAY 1 - VINCRISTINE IV 1.5 MG/M2 (MAX 2 MG), ACTINOMYCIN-D IV 1.5 MG/M2 (MAX 2 MG) ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CMU0119 -c : RHABDOMYOSARCOMA - IVAD (VINCRISTINE + DOXORUBICIN + IFOSFAMIDE + MESNA ) ; DAYS 1 AND 2 - IFOSFAMIDE 3 G/M2 + MESNA, DOXORUBICIN 30MG/M2 ; DAY 1 - VINCRISTINE 1.5 MG/M2, ACTINOMYCIN-D 1.5 MG/M2 ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0120 : EWINGS SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0120 -i : EWINGS SARCOMA - INDUCTION TREATMENT I	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0120 -i-a : EWINGS SARCOMA - INDUCTION TREATMENT - VIDE ; DAY 1 - VINCRISTINE 1.5MG/M2(MAX 2MG) IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV, IFOSFAMIDE 3G/M2IV, MESNA CONTINUOUS IV, ETOPOSIDE 150MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	8800	8800	8800	8800	8800	8800	8800	8800
CMU0120 -i-b : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0120 -i-b-1 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - VAC ; DAY 1 - VINCRISTINE 2MG/M2 (MAX 2MG) IV, DOXORUBICIN 75MG/M2 IV BOLUS, CYCLOPHOSPHAMIDE 1, 200MG/M2 IV, MESNA. ; DACTINOMYCIN 1.25MG/M2 IV CAN BE SUBSTITUTED FOR DOXORUBICIN WHEN A TOTAL DOXORUBICIN DOSE OF 375MG/M2 IS REACHED.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CMU0120 -i-b-2 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - IE ; IE CYCLES ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2 IV + MESNA + ETOPOSIDE 100MG/M2 IV. ; REPEAT EACH CYCLE EVERY 3 WEEKS FOR 17 CYCLES.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CMU0120 -i-c : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 4 DAY REGIMEN ; DAY 1 - VINCRISTINE 1.5MG/M2IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, THEN LOCAL THERAPY, FOLLOWED BY 10 ADDITIONAL CYCLES OF VAIA FOR HIGH RISK AND ; 10 ADDITIONAL CYCLES OF VAIA OR 10 CYCLES OF VACA FOR STANDARD-RISK PATIENTS	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0120 -i-d : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 24 DAY REGIMEN ; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1, 2, 22, 23, 43, AND 44 - IFOSFAMIDE 3, 000MG/M2 IV + MESNA ; DAYS 1, 2, 43, AND 44 - DOXORUBICIN 30MG/M2 IV ; DAYS 22, 23, AND 24 - DACTINOMYCIN 0.5MG/M2 IV ; AFTER COMPLETION OF ONE 9-WEEK CYCLE, LOCAL THERAPY FOLLOWED BY 3 ADDITIONAL CYCLES.	MEDICAL ONCOLOGY	18600	18600	18600	18600	18600	18600	18600	18600
CMU0120 -i-e : EWINGS SARCOMA - INDUCTION TREATMENT - VACA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + CYCLOPHOSPHAMIDE 1, 200MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 10 CYCLES.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CMU0120 -ii : EWINGS SARCOMA - MAINTENANCE TREATMENT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0120 -ii-a : EWINGS SARCOMA - MAINTENANCE TREATMENT - ETOPOSIDE/IFOSFAMIDE ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2/DAY IV + MESNA ; DAYS 1-5 - ETOPOSIDE 100MG/M2/DAY IV.	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
CMU0121 : PALLIATIVE CHEMOTHERAPY (ANY REGIMEN)- MAXIMUM PAYABLE	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
CMU0122 : CERVICAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0122 -a : CERVICAL CANCER - CISPLATIN ; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0122 -b : CERVICAL CANCER - CISPLATIN & 5FU WITH RT ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 IV OVER 96 HOURS ; REPEAT CYCLE EVERY 3 WEEKS FOR 3	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CMU0122 -c : CERVICAL CANCER - CISPLATIN & 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
CMU0123 : VULVAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0123 -a : VULVAL CANCER - CISPLATIN ; DAY 1 - 40 MG/M 2 IV	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0123 -b : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS - TOTAL 3 CYCLES	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CMU0123 -c : VULVAL CANCER - 5-FU + MITOMYCIN ; 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE),	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU0123 -e : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV	MEDICAL ONCOLOGY	11700	11700	11700	11700	11700	11700	11700	11700
CMU0124 : VAGINAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0124 -a : VAGINAL CANCER - CISPLATIN ; CISPLATIN 75MG/M2 ; ONCE WEEKLY FOR UP TO 6 DOSES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0125 : OVARIAN CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0125 -a : OVARIAN CANCER - PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 135MG/M2 CONTINUOUS IV ; DAY 2 - CISPLATIN 75-100MG/M2 ; DAY 8 - PACLITAXEL 60MG/M2 ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	9300	9300	9300	9300	9300	9300	9300	9300
CMU0125 -b : OVARIAN CANCER - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML IV ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU0125 -c : OVARIAN CANCER - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 60-75MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
CMU0126 : ENDOMETRIAL CANCER (PALLIATIVE CHEMOTHERAPY ONLY)	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
CMU0127 : OVARY- GERM CELL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0127 -a : OVARY- GERM CELL TUMOR - BEP (BLEOMYCIN + ETOPOSIDE + CISPLATIN) ; DAYS 1, 8, 15 - BLEOMYCIN 30 UNITS/WK IV, ETOPOSIDE 100 MG/M 2/DAY IV ; DAYS 1-5 - CISPLATIN 20 MG/M 2/DAY IV ; REPEAT EVERY 21 DAYS 3-4 CYCLES	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
CMU0127 -b : OVARY- GERM CELL TUMOR - EP ( ETOPOSIDE + CARBOPLATIN) ; DAY 1 - CARBOPLATIN 400 MG/M 2 IV ON DAYS 1-3 ; REPEAT EVERY 28 DAYS FOR THREE CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0128 : GESTATIONAL TROPHOBLAST DISEASES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0128 -a : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (5 DAYS REGIMEN) ; DAYS 1-5 - MTX 0.4 MG/KG/DAY IV OR IM FOR 5 DAYS, NOT TO EXCEED 25 MG/DAY ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0128 -b : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (8-DAY ALTERNATING REGIMEN) ; DAYS 1, 3, 5, AND 7 - MTX 1 MG/KG IM, ; DAYS 2, 4, 6, AND 8 - FOLINIC ACID 15 MG ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CMU0128 -c : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE + FOLINIC ACID ; DAY 1 - MTX 100 MG/M 2 IVP, THEN 200 MG/M 2 INFUSION ; DAY 2 - FOLINIC ACID 15 MG IM/PO Q12H FOR 4 DOSES ; REPEAT CYCLE EVERY 18 DAYS	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CMU0128 -d : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE - WEEKLY ; MTX 30-50 MG/M 2 IM WEEKLY	MEDICAL ONCOLOGY	1400	1400	1400	1400	1400	1400	1400	1400
CMU0128 -e : GESTATIONAL TROPHOBLAST DISEASES - ACT-D ; ACT-D 10-13 MCG/KG OR 0.5-MG FLAT DOSE IV QD FOR 5D ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
CMU0128 -f : GESTATIONAL TROPHOBLAST DISEASES - ACTINOMYCIN ; ACTINOMYCIN 1.25 MG/M 2 IV ; REPEAT EVERY 2 WEEKS	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
CMU0128 -g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (COMPLETE) ; DAY 1 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, MTX - 300 MG/M2 IV ; DAY 2 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, LEUCOVORIN - 15 MG PO/IM Q12H 4 DOSES ; DAY 8 - VINCRISTINE - 0.8 MG/M2 IV, CYCLOPHOSPHAMIDE - 600 MG/M2 IV ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CMU0129 : TESTICULAR CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0129 -a : TESTICULAR CANCER - EP ; DAYS 1-5 - ETOPOSIDE 100MG/M2, CISPLATIN 20MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
CMU0129 -b : TESTICULAR CANCER - BEP ; DAYS 1-5 - CISPLATIN 20MG/M2, ETOPOSIDE 100MG/M2 ; DAYS 1, 8, AND 15 OR DAYS 2, 9, OR 16 - BLEOMYCIN 30 UNITS IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
CMU0129 -c : TESTICULAR CANCER - VIP ; DAY 1 (BEFORE IFOSFAMIDE) - MESNA 120MG/M2 IV ; DAYS 1-5 - ETOPOSIDE 75MG/M2 IV, MESNA 1, 200MG/M2 IV, IFOSFAMIDE 1, 200MG/M2 IV + CISPLATIN 20MG/M2. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
CMU0130 : PROSTATE CANCERPROSTATE CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0130 -a : PROSTATE CANCER - DOCETAXEL + PREDNISONE ; DAY 1 - DOCETAXEL 75MG/M2 IV, PREDNISONE 5MG ORALLY TWICE DAILY. ; ONCE EVERY 3 WEEKS, REPEAT FOR UP TO 10 CYCLES IF TOLERATED	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0130 -c : PROSTATE CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CMU0131 : FEBRILE NEUTROPENIA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0131 -a : FEBRILE NEUTROPENIA - FIRST-LINE MONOTHERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G ; CEFEPIME 2 G ; MEROPENEM 1 G ; IMIPENEM-CILASTATIN 500 MG	MEDICAL ONCOLOGY	14200	14200	14200	14200	14200	14200	14200	14200
CMU0131 -b : FEBRILE NEUTROPENIA - SECOND-LINE DUAL THERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G IV PLUS AN AMINOGLYCOSIDE ; MEROPENEM 1 G IV PLUS AN AMINOGLYCOSIDE ; IMIPENEM-CILASTATIN 500 MG IV PLUS AN AMINOGLYCOSIDE	MEDICAL ONCOLOGY	20500	20500	20500	20500	20500	20500	20500	20500
CMU0132 : THYROID CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0132 -a : THYROID CANCER - SORAFENIB ; SORAFENIB 400 MG PO BID	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CMU0132 -b : THYROID CANCER - SUNITINIB ; SUNITINIB 50 MG	MEDICAL ONCOLOGY	29900	29900	29900	29900	29900	29900	29900	29900
CMU0132 -c : THYROID CANCER - PAZOPANIB	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CMU0132 -d : THYROID CANCER - DOXORUBICIN ; DOXORUBICIN 60 MG/M2 AS MONOTHERAPY OR IN COMBINATION WITH CISPLATIN 40 MG/M2	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CMU0133 : THYMOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0133 -a : THYMOMA - CAP ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 50MG/M2 IV, CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 8 CYCLES.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CMU0133 -b : THYMOMA - CAPP ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV ; DAYS 1-3 - CISPLATIN 30MG/M2 IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 ; DAYS 1-5 - PREDNISONE 100MG. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0133 -c : THYMOMA - ADOC ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 40MG/M2 IV ; DAY 3 - VINCRISTINE 0.6MG/M2 IV ; DAY 4 - CYCLOPHOSPHAMIDE 700MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 5 CYCLES.	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CMU0133 -d : THYMOMA - PE ; DAY 1 - CISPLATIN 60MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 120MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 8 CYCLES.	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CMU0133 -e : THYMOMA - VIP ; DAYS 1-4 - ETOPOSIDE 75MG/M2 IV, IFOSFAMIDE 1.2G/M2 IV, CISPLATIN 20MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0133 -f : THYMOMA - CARBOPLATIN+PACLITAXEL ; DAY 1 - PACLITAXEL 225MG/M2 IV, CARBOPLATIN AUC = 6 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 6 CYCLES.	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CMU0134 : BRAIN CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -i : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -i-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - COMBINATION PCV (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY. ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY. ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0134 -i-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (7 WEEKS) ; DAYS 1-49 - TEMOZOLOMIDE 75MG/M2 ORALLY. ; REPEAT CYCLE EVERY 11 WEEKS (7 WEEKS ON/4 WEEKS OFF) FOR 6 CYCLES.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0134 -i-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; TEMOZOLOMIDE MONTHLY 5-DAY COURSES AT DOSES OF 180 - 200MG/M2/DAY	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -i-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (3 WEEKS) ; DAYS 1-21 - TEMOZOLOMIDE 75MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 28 DAYS.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CMU0134 -ii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMASSYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -ii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 4 WEEKS UNTIL DISEASE PROGRESSION OR FOR UP TO 24 CYCLES.	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -ii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV WITH DEFERRED RT (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0134 -ii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -ii-c-1 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY)	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CMU0134 -ii-c-2 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - ADJUVANT TEMOZOLOMIDE - PRECEEDED BY CONCURRENT TEMOZOLOMIDE (WITH RT) ; TEMOZOLOMIDE 150-200MG/M2/DAY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -ii-d : ADJUVANT TEMOZOLOMIDE	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -ii-e : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV FOR 1P19Q CO-DELETED (WITH RADIOTHERAPY) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. FOR 6 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0134 -iii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -iii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY)	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CMU0134 -iii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - ADJUVANT TEMOZOLOMIDE (PRECEEDED BY CONCURRENT TEMOZOLZMIDE) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -iii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (POST RT) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -iii-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (200MG) WITH STANDARD RT ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2, ORALLY	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CMU0134 -iv : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -iv-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + LOMUSTINE ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; ; DURING CRANIO-SPINAL RT	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CMU0134 -iv-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0134 -v : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMAPRIMARY CNS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-a : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPYHIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-a-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + CYTARABINE ; DAY 1 - MTX 3.5G/M2 ; DAYS 2-3 - CYTARABINE 2G/M2 IV TWICE A DAY.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0134 -v-a-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + LEUCOVORIN + IFOSFAMIDE + MESNA ; DAY 1 - MTX 4GM/M2 IV, ; DAYS 2-5 - LEUCOVORIN 20-25MG IV (UPTO 40MG) ; DAYS 3-5 - IFOSFAMIDE 1.5GM/M2 IV + MESNA 400MG IV	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CMU0134 -v-b : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY HIGH DOSE METHOTREXATE (MTX 2.5-4.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-b-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + MTX + VINCRISTINE +PROCARBAZINE ; DAY 1 - RITUXIMAB 500MG/M2 IV ; DAY 2 - MTX 3.5MG/M2 IV PLUS VINCRISTINE 1.4MG/M2 ; PROCARBAZINE 100MG/M2/DAY ADMINISTERED FOR 7 DAYS WITH ODD-NUMBERED CYCLES	MEDICAL ONCOLOGY	44000	44000	44000	44000	44000	44000	44000	44000
CMU0134 -v-c : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY +/- MONOCLONAL ANTIBODY HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-c-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE INDUCTION ; MTX 8G/M2 IV ; REPEAT EVERY 2 WEEKS UNTIL COMPLETE RESPONSE ACHIEVED OR MAX OF 8 CYCLES REACHED. ;	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CMU0134 -v-c-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE CONSOLIDATION ; MTX 8G/M2 IV ADMINISTERED ; REPEAT EVERY 2 WEEKS FOR 2 CYCLES.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CMU0134 -v-c-3-i : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 1-4) ; DAY 1 - MTX 8G/M2 IV, RITUXIMAB 375MG/M2 IV. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	27600	27600	27600	27600	27600	27600	27600	27600
CMU0134 -v-c-3-ii : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 5-11) ; MTX 8G/M2 IV ADMINISTERED EVERY 4 WEEKS FOR 11 CYCLES. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CMU0134 -v-d : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-d-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - INDUCTION ; DAY 1 - RITUXIMAB 375MG/M2 IV, FOLLOWED BY ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY, AFTER RITUXIMAB INFUSION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	22700	22700	22700	22700	22700	22700	22700	22700
CMU0134 -v-d-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - MAINTANANCEDAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY. ; REPEAT CYCLE EVERY 4 WEEKS FOR 8 CYCLES.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CMU0134 -v-e : BRAIN CARCINOMA - MENINGIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0134 -v-e-1 : BRAIN CARCINOMA - MENINGIOMA - INTERFERON-ALFAINTERFERON-ALFA ; ALPHA-IFN 106 UNITS/M2 SC EVERY OTHER DAY FOR 4 WEEKS. ; REPEAT CYCLE EVERY 4 WEEKS. ;	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CMU0134 -v-e-2 : BRAIN CARCINOMA - MENINGIOMA -SOMATOSTATIN ANALOG ; SANDOSTATIN LAR DEPOT 10-30MG IM ; REPEAT EVERY 4 WEEKS. ;	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
CMU0134 -v-e-3 : BRAIN CARCINOMA - MENINGIOMA - SUNITINIB ; DAYS 1-28 - SUNITINIB 50MG ORALLY DAILY. ; REPEAT CYCLE EVERY 42 DAYS.	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CMU0135 : HEAD AND NECK CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -i : HEAD AND NECK CANCER - SQUAMOUS CELL CANCERS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -i-a : HEAD AND NECK CANCER - HIGH DOSE CISPLATIN ; CISPLATIN 100MG/M2 IV + CONCURRENT RADIOTHERAPY; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CMU0135 -i-b : HEAD AND NECK CANCER - CARBOPLATIN + INFUSIONAL 5-FU ; DAYS 1-4 - 5-FU 600MG/M2/DAY AS CONTINUOUS IV I, CARBOPLATIN 70MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES (GIVEN CONCURRENTLY WITH RADIOTHERAPY).	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CMU0135 -i-c : HEAD AND NECK CANCER - 5-FU + HYDROXYUREA ; DAY 1 - HYDROXYUREA 1, 000MG ORALLY EVERY 12 HOURS (11 DOSES/CYCLE), 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
CMU0135 -i-d : HEAD AND NECK CANCER - CISPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 30MG/M2 IV (EVERY MONDAY), ; DAY 2 - CISPLATIN 20MG/M2 IV (EVERY TUESDAY). ; REPEAT CYCLE EVERY WEEK FOR 7 CYCLES, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CMU0135 -i-e : HEAD AND NECK CANCER - CISPLATIN + INFUSIONAL 5-FU ; DAY 1 - CISPLATIN 60MG/M2 OVER ; DAYS 1-5 - 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CMU0135 -i-f : HEAD AND NECK CANCER - CARBOPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 40-45MG/M2, CARBOPLATIN 100MG/M2 ; REPEAT CYCLE EVERY WEEK FOR 8 CYCLES, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0135 -i-g : HEAD AND NECK CANCER - WEEKLY CISPLATIN ; CISPLATIN 40MG/M2 IV PER WEEK	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0135 -i-h : HEAD AND NECK CANCER - CISPLATIN (FOR HIGH RISK OROPHARYNGEAL CARCINOMA) ; DAYS 1, 22, AND 43 - CISPLATIN 100MG/M2 IV + RADIOTHERAPY.	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CMU0135 -i-i : HEAD AND NECK CANCER - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV, ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV. ; REPEAT EVERY 3 WEEKS FOR UP TO 4 CYCLES.	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CMU0135 -ii : HEAD AND NECK CANCER - NASOPHARYNX CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -ii-a : NASOPHARYNX CANCER - CONCURRENT CISPLATIN FOLLOWED BY CONCURRENT CISPLATIN +5FUC ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -ii-a-1 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN (FOLLOWED BY CONCURRENT CISPLATIN +5FU) ; DAY 1 - CISPLATIN 100MG/M2 IV; PLUS RADIOTHERAPY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; FOLLOWED BY CONCURRENT CISPLATIN +5FU	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CMU0135 -ii-a-2 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN +5FU - PRECEEDED BY (CONCURRENT CISPLATIN 3 CYCLES) ; DAYS 1-4 - CISPLATIN 80MG/M2/DAY, 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CMU0135 -ii-b : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN FOLLOWED BY CONCURRENT CARBOPLATIN +5FU	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -ii-b-1 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN - (FOLLOWED BY CONCURRENT CARBOPLATIN +5FU) ; DAY 1 - CARBOPLATIN AUC 6MG/MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES;	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
CMU0135 -ii-b-2 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN +5FU - PRECEEDED BY (CONCURRENT CARBOPLATIN ) ; DAY 1 - CARBOPLATIN AUC 5MG/MIN/ML IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	14200	14200	14200	14200	14200	14200	14200	14200
CMU0135 -ii-c : NASOPHARYNX CANCER - CONCURRENT CISPLATIN ; CISPLATIN 40MG/M2 ; REPEAT WEEKLY FOR 7 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0135 -ii-d : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU FOLLOWED BY CISPLATIN ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -ii-d-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU - FOLLOWED BY CISPLATIN AFTER 3 CYCLES ; DAY 1 - DOCETAXEL 70MG/M2 IV, CISPLATIN 75MG/M2 IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT EVERY WEEK FOR 3 CYCLES	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0135 -ii-d-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 3 CYCLES OF DOCETAXEL + 5-FU ; DAY 1 - CISPLATIN 100MG/M2; ; REPEAT EVERY 3 WEEKS, TILL RADIATION	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CMU0135 -ii-e : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0135 -ii-e-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN - FOLLOWED BY CISPLATIN AFTER 2 CYCLES ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR TWO CYCLES	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
CMU0135 -ii-e-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 2 CYCLES OF DOCETAXEL + CISPLATIN ; CISPLATIN 40MG/M2 IV ; WEEKLY CONCURRENT WITH RADIOTHERAPY.	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
CMU0135 -ii-f : NASOPHARYNX CANCER - CISPLATIN + 5-FU ; DAY 1 - CISPLATIN 100MG/M2/DAY IV. ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION FOR 4 DAYS. ; REPEAT CYCLE EVERY 3 WEEKS FOR A MINIMUM OF 6 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CMU0135 -i-j : HEAD AND NECK CANCER - PACLITAXEL + CISPLATIN+ INFUSIONAL 5-FU ; DAY 1 - PACLITAXEL 175MG/M2 ; DAY 2 - CISPLATIN 100MG/M2 ; DAY 2-6 - 5-FU 500MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CMU0136 : RENAL CELL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0136 -a : RENAL CELL CARCINOMA - PAZOPANIB	MEDICAL ONCOLOGY	20000	20000	20000	20000	20000	20000	20000	20000
CMU0136 -b : RENAL CELL CARCINOMA - SUNITINIB	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CMU0136 -c : RENAL CELL CARCINOMA - SORAFENIB	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CMU0136 Ia : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
CMU0136 Ib : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
CMU0136 Ic : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - BEVACIZUMAB + IFN-ALPHA ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS + IFN-ALPHA.	MEDICAL ONCOLOGY	70100	70100	70100	70100	70100	70100	70100	70100
CMU0136 Id : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0136 IIa : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	39100	39100	39100	39100	39100	39100	39100	39100
CMU0136 IIb : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
CMU0136 IIc : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0136 IId : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
CMU0136 IIe : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS.	MEDICAL ONCOLOGY	69600	69600	69600	69600	69600	69600	69600	69600
CMU0136 IIIa : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
CMU0136 IIIb : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS.	MEDICAL ONCOLOGY	69600	69600	69600	69600	69600	69600	69600	69600
CMU0136 IIIc : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	39100	39100	39100	39100	39100	39100	39100	39100
CMU0136 IIId : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - ERLOTINIB ; ERLOTINIB 150MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CMU0136 IIIe : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
CMU0136 IIIf : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0137 : UNKNOWN PRIMARY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0137 -i : UNKNOWN PRIMARY - ADENOCARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0137 -i-a : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN + ETOPOSIDE ; DAY 1 - PACLITAXEL 200 MG/M 2 IV, CARBOPLATIN AUC 6 ; DAYS 1-10 - ETOPOSIDE 50 MG PO ALTERNATING WITH 100 MG DAILY ; REPEAT EVERY 21DAYS FOR 2-3 CYCLES; RESTAGE, CAN BE TREATED UPTO 8 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
CMU0137 -i-b : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 200 MG/M 2, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CMU0137 -i-c : UNKNOWN PRIMARY - ADENOCARCINOMA - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 65MG/M2 IV, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0137 -i-d : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + CISPLATIN ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CMU0137 -i-e : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + DOCETAXEL ; DAY 1 AND 8 - GEMCITABINE 1000MG/M2 IV OVER 30 MINUTES ; DAY 8 - DOCETAXEL 75MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR A MAXIMUM OF 6 CYCLES	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CMU0137 -i-f : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + IRINOTECAN ; DAYS 1 AND 8 - IRINOTECAN 100MG/M2 IV, GEMCITABINE 1000MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.RESTAGE EVERY 2-3 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CMU0137 -i-g : UNKNOWN PRIMARY - ADENOCARCINOMA - MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
CMU0137 -i-h : UNKNOWN PRIMARY - ADENOCARCINOMA - CAPEOX ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAY 1-14 - CAPECITABINE 850-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 16 CYCLES.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0137 -i-i : UNKNOWN PRIMARY - ADENOCARCINOMA - IRINOTECAN + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
CMU0137 -ii : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0137 -ii-a : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - PACLITAXEL + CISPLATIN + 5-FU ; PACLITAXEL 175 MG/M 2 IV, ; DAY 2 - CISPLATIN 100 MG/M 2 IV, ; DAY 5-FU (5-FLUOROURACIL) 500 MG/M 2/DAY IV ; REPEAT EVERY 21D	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0137 -ii-b : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0137 -ii-c : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 6MG PER MIN/ML IV OVER 30 MINUTES + PACLITAXEL 200MG/M2 IV OVER 3 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES IN RESPONDING PATIENTS AND FOR 6 CYCLES MAXIMUM IN PATIENTS WITH STABLE DISEASE	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CMU0137 -ii-d : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + GEMCITABINE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CMU0137 -ii-e : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES.	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
CMU0137 -ii-f : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV + CISPLATIN 60MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0137 -ii-g : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV OVER 30 MINUTES + CARBOPLATIN AUC 5MG PER MIN/ML IV OVER 30 MINUTES. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
CMU0137 -ii-h : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 60MG/M2 IV + CISPLATIN 80MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 2 CYCLES AND AN ADDITIONAL 4 CYCLES UNTIL DISEASE PROGRESSION IS DEMONSTRATED	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CMU0137 -iii : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0137 -ii-i : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU0137 -iii-b : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS - ETOPOSIDE + CISPLATIN ; DAYS 1-3 - ETOPOSIDE 100 MG/M 2 ; DAYS 2-3 - CISPLATIN 45 MG/M 2 IV ; REPEAT EVERY 28 DAYS	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CMU0137 -ii-j : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + FLUOROURACIL ; DAYS 1-5 - CISPLATIN 20MG/M2 IV ; DAYS 1-5 - FLUOROURACIL 700MG/M2/DAY IV VIA CONTINUOUS INFUSION OVER 24 HOURS. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU0138 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0138 -a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - GEMCITABINE + CISPLATIN ; DAYS 1 AND 8 - CISPLATIN 25MG/M2 IV, GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 4 CYCLES, RE-EVALUATE AND CONTINUE AN ADDITIONAL 4 CYCLES IF WARRANTED	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CMU0138 -b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV	MEDICAL ONCOLOGY	4300	4300	4300	4300	4300	4300	4300	4300
CMU0138 -c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - CAPECITABINE ; CAPECITABINE ORAL ; REPEAT EVERY 21 DAYS	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0139 : PANCREAS CARCINOMAPANCREAS CARCINOMA -	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0139 -i : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0139 -i-a : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 4 WEEKS FOR SIX CYCLES	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CMU0139 -ii : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0139 -ii-a : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - 5-FU + LEUCOVORIN ; DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CMU0139 -ii-b : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - GEMCITABINE & 5FU ; PRIOR TO CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 MONTHS.	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CMU0139 -ii-c : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - CONTINUOUS INFUSION 5-FU (WITH RADIATION) ; PRIOR TO CHEMORADIATION - ; DAYS 1-21 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1-28 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 6 WEEKS FOR 3 MONTHS.	MEDICAL ONCOLOGY	21800	21800	21800	21800	21800	21800	21800	21800
CMU0139 -iii : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - NEOADJUVANT THERAPY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0139 -iii-a : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - CAPECITABINECAPECITABINE ; CAPECITABINE ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 52 WEEKS.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0140 : PERI AMPULLARY CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0140 -a : PERI AMPULLARY CARCINOMA - 5-FU ; FLUOROURACIL 425 MG/M2 ADMINISTERED ON DAYS 1 TO 5 AND 29-33	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CMU0141 : NEURO ENDOCRINE CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0141 -a : NEURO ENDOCRINE CARCINOMA - ALL NECS ARE COVERED UNDER ORGAN CANCERS. IF UNCOVERED - UNLISTED ONLY.	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0142 : SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0142 -i : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0142 -i-a : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST - IMATINIB ; IMATINIB 400MG ORALLY ONCE DAILY TO TWICE DAILY	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU0142 -ii : SARCOMA - SOFT TISSUE SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0142 -ii-a : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + DACARBAZINE (AD) ; DAYS 1-4 - DOXORUBICIN 60MG/M2 + DACARBAZINE 750MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	12100	12100	12100	12100	12100	12100	12100	12100
CMU0142 -ii-b : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + IFOSFAMIDE + MESNA ; DAYS 1 AND 2 - DOXORUBICIN 30MG/M2/DAY IV, IFOSFAMIDE 3, 750MG/M2/DAY IV, MESNA 750MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CMU0142 -ii-c : SARCOMA - SOFT TISSUE SARCOMA - MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID) ; DAYS 1-3 - DOXORUBICIN 20MG/M2/DAY, IFOSFAMIDE 2, 500MG/M2/DAY, DACARBAZINE 300MG/M2/DAY IV ; DAYS 1-4 - MESNA 2, 500MG/M2/DAY IV FOR 84 TO 96 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	11300	11300	11300	11300	11300	11300	11300	11300
CMU0142 -ii-d : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE + EPIRUBICIN + MESNA ; DAYS 1 AND 2 - EPIRUBICIN 60MG/M2/DAY IV ; DAYS 1-5 - IFOSFAMIDE 1.8G/M2/DAY IV + MESNA. ; REPEAT CYCLE EVERY 3 WEEKS FOR 5 CYCLES.	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
CMU0142 -ii-e : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DOCETAXEL ; DAYS 1 AND 8 - GEMCITABINE 900MG/M2 IV ; DAY 8 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CMU0142 -ii-f : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + VINORELBINE ; DAYS 1 AND 8 - VINORELBINE 25MG/M2 IV, GEMCITABINE 800MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	15500	15500	15500	15500	15500	15500	15500	15500
CMU0142 -ii-g : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DACARBAZINE ; DAY 1 - GEMCITABINE 1, 800MG/M2 IV + DACARBAZINE 500MG/M2 IV. ; REPEAT CYCLE EVER 2 WEEKS FOR A TOTAL OF 12 CYCLES;	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU0142 -ii-h : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN ; DOXORUBICIN 60-75MG/M2 IV ; ONCE EVERY 3 WEEKS	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CMU0142 -ii-i : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAYS 1-3 - IFOSFAMIDE 2, 000-3, 000MG/M2/DAY IV FOR 3 TO 4 DAYS + MESNA ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
CMU0142 -ii-j : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAY 1 - IFOSFAMIDE 5, 000MG/M2 + MESNA 5, 000MG/M2 IV ; DAY 2 - MESNA 400-600MG/M2 IV ; IFOSFAMIDE, MESNA ; REPEAT EVERY 3 WEEKS	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CMU0142 -ii-k : SARCOMA - SOFT TISSUE SARCOMA - EPIRUBICIN ; EPIRUBICIN 160MG/M2 IV ; REPEAT EVERY 3 WEEKS	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CMU0142 -ii-l : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE ; DAYS 1 AND 8 - GEMCITABINE 1, 200MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CMU0142 -ii-m : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (I) ; DACARBAZINE 250MG/M2/DAY IV FOR 5 DAYS ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU0142 -ii-n : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (II) ; DACARBAZINE 800-1, 000MG/M2 IV ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CMU0142 -ii-o : SARCOMA - SOFT TISSUE SARCOMA - LIPOSOMAL DOXORUBICIN ; LIPOSOMAL DOXORUBICIN 30-50MG/M2 IV ; REPEAT EVERY 4 WEEKS.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CMU0142 -ii-p : SARCOMA - SOFT TISSUE SARCOMA - TEMOZOLOMIDE ; TEMOZOLOMIDE 200MG/M2 ORALLY TWICE DAILY FOR 5 DAYS, FOLLOWED BY 9 DOSES OF 90MG/M2 ORALLY ; REPEAT EVERY 4 WEEKS	MEDICAL ONCOLOGY	4400	4400	4400	4400	4400	4400	4400	4400
CMU0143 : PRIMITIVE NEURO ECTODERMAL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0143 -a : PRIMITIVE NEURO ECTODERMAL TUMOR - WEEKLY VINCRISTINE ; VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; FOR 5 TO 6 WEEKS	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CMU0143 -b : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + LOMUSTINE ; DURING CRANIOSPINAL RADIOTHERAPY (RT) ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; UP TO MAX 8 DOSES	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CMU0143 -c : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU0144 : ANAL CANAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0144 -a : ANAL CANAL CANCER - 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY IV ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU0144 -b : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (I) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY.	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CMU0144 -c : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (II) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAY 1 - MITOMYCIN 12MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0144 -d : ANAL CANAL CANCER - CISPLATIN + 5-FU ; DAYS 1-5 - 5-FU 1, 000MG/M2/DAY IV ; DAY 2 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CMU0145 : CA-PENIS	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CMU0145-a : CA-PENIS - CISPLATIN + 5-FU ; DAY 1 - 5 FU 1000mg/m2 D1-D4 and Day 1 - Cisplatin 75mg/m2 Every 4 weeks	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CMU0145-b : CA-PENIS -Paclitaxel; Paclitaxel 80 mg/m2 D1 every week	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CMU0145-c : CA-PENIS - Paclitaxel; Paclitaxel 175 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU0975 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A : ALL LEUKEMIA( CHEMOTHERAPHY)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-I : CHRONIC MYELOID LEUKEMIA (CML) - CHRONIC MYELOID LEUKEMIA (CML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-II : ACUTE MYELOID LEUKEMIA (AML) - ACUTE MYELOID LEUKEMIA (AML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-II-a : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 1 - AGE	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0975 A-I-i-a : CHRONIC MYELOID LEUKEMIA (CML) - IMATINIB - LOW TO INTERMEDIATE RISK - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CMU0975 A-II-b : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
CMU0975 A-I-i-b : CHRONIC MYELOID LEUKEMIA (CML) - NILOTINIB - LOW TO INTERMEDIATE RISK - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CMU0975 A-II-c : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 2 - AGE	MEDICAL ONCOLOGY	10900	10900	10900	10900	10900	10900	10900	10900
CMU0975 A-II-d : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
CMU0975 A-II-e : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
CMU0975 A-II-f : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN (90MG) + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0975 A-II-g : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
CMU0975 A-II-h : ACUTE MYELOID LEUKEMIA (AML) - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	10800	10800	10800	10800	10800	10800	10800	10800
CMU0975 A-II-i : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CMU0975 A-III : CHRONICLYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-I-ii : CHRONICMYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-I-ii-a : CML - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - INDUCTION - 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY - CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M2 - OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY - OLDER THAN 60 Y) IV ON DAYS 1-3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1-21 (DAYS 1-7- OLDER THAN 60 Y) + L-ASPARAGINASE 6000 U/M 2 SC ON DAYS 5, 8, 11, 15, 18, AND 22	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
CMU0975 A-III-a-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 1 - DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY	MEDICAL ONCOLOGY	1200	1200	1200	1200	1200	1200	1200	1200
CMU0975 A-III-a-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 3 - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY	MEDICAL ONCOLOGY	21800	21800	21800	21800	21800	21800	21800	21800
CMU0975 A-III-a-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 4-8 - DAY 1; RITUXIMAB 500MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY.	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
CMU0975 A-III-a-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - MAINTANANCE - RITUXIMAB - RITUXIMAB AT DOSE OF 375MG/M2 IV EVERY 2 MONTHS FOR 2 YEARS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
CMU0975 A-III-b : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB DAY 1, 8, 15, AND 22 - DAY 1, 8, 15, AND 22; RITUXIMAB 375MG/M2/DAY IV.	MEDICAL ONCOLOGY	85500	85500	85500	85500	85500	85500	85500	85500
CMU0975 A-I-ii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CMU0975 A-III-c : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - CHLORAMBUCIL - DAYS 1-28; CHLORAMBUCIL 0.4MG/KG/DAY WITH AN INCREASE TO 0.8MG/KG ORALLY DAILY. REPEAT CYCLE EVERY 28 DAYS FOR 12 CYCLES	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CMU0975 A-I-ii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CMU0975 A-III-d-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLE -1) - DAY 0; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
CMU0975 A-III-d-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLES 2-6) - RITUXIMAB 500MG/M2 ON DAY 1 AND BENDAMUSTINE - 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	32300	32300	32300	32300	32300	32300	32300	32300
CMU0975 A-III-d-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (70MG) (CYCLE -1) - DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
CMU0975 A-III-d-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (90 MG) (CYCLES 2-6) - DAY 1 - BENDAMUSTINE 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0975 A-III-e : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG OR 500/M2 IV, DAYS 1-3; FLUDARABINE 25MG/M2/DAY IV PLUS CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	27200	27200	27200	27200	27200	27200	27200	27200
CMU0975 A-III-f : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + RITUXIMAB (FR) - DAYS 1-5; FLUDARABINE 25MG/M2 IV, DAY 1; RITUXIMAB 50MG/M2 IV, DAY 3; RITUXIMAB 325MG/M2 IV, DAY 5; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH RITUXIMAB GIVEN AT A DOSE OF 375MG/M2 ON DAY 1 OF SUBSEQUENT CYCLES.	MEDICAL ONCOLOGY	57800	57800	57800	57800	57800	57800	57800	57800
CMU0975 A-III-g : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB + RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV	MEDICAL ONCOLOGY	92700	92700	92700	92700	92700	92700	92700	92700
CMU0975 A-III-h : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB WITHOUT RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU0975 A-III-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE + RITUXIMAB - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	88400	88400	88400	88400	88400	88400	88400	88400
CMU0975 A-I-iii : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-I-iii-a : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG/M2)+ CYTARABINE - < 60 YEARS, DAYS 1-3; DAUNORUBICIN 90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0975 A-I-iii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE + CLADRIBINE - AGE	MEDICAL ONCOLOGY	10900	10900	10900	10900	10900	10900	10900	10900
CMU0975 A-I-iii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
CMU0975 A-I-iii-d : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG) + CYTARABINE - AGE >60 YEARS - DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
CMU0975 A-I-iii-e : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE (HIGH DOSE) - DAYS 1-3; IDARUBICIN 12MG/M2, DAYS 1-6; HIGH-DOSE CYTARABINE 2G/M2 IV EVERY 12 HOURS, OR DAYS 1-4; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
CMU0975 A-I-iii-f : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
CMU0975 A-I-iii-g : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
CMU0975 A-I-iii-h : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CMU0975 A-I-iii-i : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CMU0975 A-III-j : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CMU0975 A-II-j : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-5; DECITABINE 20MG/M2 IV FOR A 4-WEEK CYCLE.	MEDICAL ONCOLOGY	26300	26300	26300	26300	26300	26300	26300	26300
CMU0975 A-II-k : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS	MEDICAL ONCOLOGY	81400	81400	81400	81400	81400	81400	81400	81400
CMU0975 A-II-l : ACUTE MYELOID LEUKEMIA (AML) - HYDROXYUREA - AGE ?60 YEARS, HYDROXYUREA 10-70MG/KG/DAY ORALLY IN DIVIDED DOSES.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CMU0975 A-II-m : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - HIGH DOSE - AGE	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
CMU0975 A-II-n : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + IDARUBICIN + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; IDARUBICIN 10MG/M2 IV.	MEDICAL ONCOLOGY	89400	89400	89400	89400	89400	89400	89400	89400
CMU0975 A-II-o : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + MITOXANTRONE + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; MITOXANTRONE 10MG/M2 IV.	MEDICAL ONCOLOGY	42700	42700	42700	42700	42700	42700	42700	42700
CMU0975 A-II-p : ACUTE MYELOID LEUKEMIA (AML) - FLUDARABINE + CYTARABINE + IDARUBICIN + GCSF -DAYS 1-5; FLUDARABINE 30MG/M2 IV OVER 0.5 HOURS, DAYS 1-5; CYTARABINE 2G/M2 IV OVER 4 HOURS, DAYS 0 TO POLYMORPHONUCLEAR RECOVERY (>0.5 X 109/L); G-CSF 5MCG/KG OR 300MCG/M2. (G-CSF MAY ALSO START ON DAY +6 UNTIL ENGRAFTMENT.) + DAYS 1-3; IDARUBICIN 10MG/M2 IV.	MEDICAL ONCOLOGY	70100	70100	70100	70100	70100	70100	70100	70100
CMU0975 A-II-q : ACUTE MYELOID LEUKEMIA (AML) - ETOPOSIDE +CYTARABINE+MITOXANTRONE - ETOPOSIDE +CYTARABINE+MITOXANTRONE, DAYS 1-6; ETOPOSIDE 80MG/M2 IV OVER 1 HOUR, DAYS 1-6; CYTARABINE 1G/M2 IV OVER 6 HOURS + DAYS 1-6; MITOXANTRONE 6MG/M2 IV BOLUS	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU0975 A-II-r : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE SC - DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CMU0975 A-II-s : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS	MEDICAL ONCOLOGY	81400	81400	81400	81400	81400	81400	81400	81400
CMU0975 A-II-t : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - DAYS 1-5; DECITABINE 20MG/M2 IV EVERY 28 DAYS.	MEDICAL ONCOLOGY	26800	26800	26800	26800	26800	26800	26800	26800
CMU0975 A-IV : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-IV-i : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-IV-i-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 INDUCTION PHASE; INDUCTION; 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY; CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M 2 IF PATIENTS OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY IF PATIENTS OLDER THAN 60 Y) IV ON DAYS 1 - 3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1 - 21 (DAYS 1 - 7 IF PATIENTS OLDER THAN 60 Y);	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
CMU0975 A-IV-i-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 - (3 WEEKS); DAY 1 - METHOTREXATE (MTX) INTRATHECALLY (IT), ETOPOSIDE 100MG/M2/DAY INTRAVENOUSLY (IV), IFOSFAMIDE 3.4G/M2/DAY IV; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY; DAYS 6 - 15 - FILGRASTIM 5G/KG/DAY SUBCUTANEOUSLY (SC) +/- IMATINIB; DAYS 8 AND 15 - CNS LEUKEMIA ONLY - MTX IT, HYDROCORTISONE IT, CYTARABINE IT;	MEDICAL ONCOLOGY	18000	18000	18000	18000	18000	18000	18000	18000
CMU0975 A-IV-i-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 (3 WEEKS); DAY 1 - AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT + MTX 5G/M2 IV OVER 24 HOURS; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF PATIENT DOES NOT ACHIEVE COUNT RECOVERY WITHIN 2 WEEKS OF LAST DOSE OF PREVIOUS COURSE); DAYS 2 - 3 - LEUCOVORIN 75MG/M2 36 HOURS AFTER MTX, FOLLOWED BY 15MG/M2 IV OR ORALLY EVERY 6 HOURS FOR 6 DOSES + CYTARABINE 3G/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4 - 13 - FILGRASTIM 5G/KG/DAY SC	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
CMU0975 A-IV-i-a-4 : ALL - PH(+) AYA - COG AALL-0031 REINDUCTION ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; DAYS 1 - 2 - DAUNORUBICIN 45MG/M2/DAY IV BOLUS; DAYS 1 - 21 - DEXAMETHASONE 6MG/M2/DAY ORALLY +/- IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 3 - 4 - CYCLOPHOSPHAMIDE 250MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES + MESNA 125MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4, 6, 8, 10, 12, 15, 17, 19, AND 21 - L - ASPARAGINASE 6, 000 IU/M2 INTRAMUSCULARLY (IM); DAYS 5 - 14 - FILGRASTIM 5G/KG/DAY SC; DAYS 8 AND 15 - VINCRISTINE 1.5MG/M2 IV; DAY 15 - MTX IT, HYDROCORTISONE IT, CYTARABINE IT.	MEDICAL ONCOLOGY	26600	26600	26600	26600	26600	26600	26600	26600
CMU0975 A-IV-i-a-5 : ALL - PH(+) AYA - COG AALL-0031 INTENSIFICATION; DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + MTX IV; DAYS 1-63 - IMATINIB ORAL; DAYS 2-3 - LEUCOVORIN ; DAY 8 - MTX IV; DAYS 9-10 - LEUCOVORIN; DAY 15 - MTX , HYDROCORTISONE , CYTARABINE - IT; DAYS 15-19 - ETOPOSIDE + CYCLOPHOSPHAMIDE + MESNA - IV; DAYS 20-29 - FILGRASTIM SC; DAYS 36-37 - CYTARABINE; DAY 37 - L - ASPARAGINASE IM +/- IMATINIB; DAYS 43-44 - CYTARABINE IV; DAY 44 - L - ASPARAGINASE IM +/- IMATINIB;	MEDICAL ONCOLOGY	43500	43500	43500	43500	43500	43500	43500	43500
CMU0975 A-IV-i-a-6 : ALL - PH(+) AYA - COG AALL-0031 MAINTENANCE CYCLES 1-4 (8 WEEKS); DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE + MTX IV; DAYS 1 - 5 - DEXA; DAYS 1 - 56 - IMATINIB; DAY 2 - LEUCOVORIN 36 HOURS AFTER MTX; DAYS 8, 15, AND 22 - MTX ORAL; DAYS 8 - 28 - 6-MP; DAY 29 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE IV; DAYS 29 - 33 - DEXA; DAYS 29 - 40 - IMATINIB; DAYS 36 - 40 - ETOPOSIDE + CYCLOPHOSPHAMIDE IV; DAYS 41 - 50 - FILGRASTIM SC;	MEDICAL ONCOLOGY	37400	37400	37400	37400	37400	37400	37400	37400
CMU0975 A-IV-i-a-7 : ALL - PH(+) AYA -COG AALL-0031 MAINTENANCE CYCLES 5-12 (8 WEEKS); CYCLE 5 ONLY - CRANIAL IRRADIATION 12 GY; DAY 1 - VINCRISTINE 1.5MG/M2 IV; DAYS 1 - 5 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 1 - 14 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 8, 15, AND 22 - MTX 20MG/M2/WEEK ORALLY; DAYS 8 - 28 - 6 - MP 75MG/M2/DAY; DAY 29 - VINCRISTINE 1.5MG/M2 IV; DAYS 29 - 33 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 29 - 42 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAY 36 - MTX 20MG/M2/WEEK ORALLY; DAYS 36 - 56 - 6 - MP 75MG/M2/DAY; DAYS 43 AND 50 - MTX 20MG/M2/WEEK ORALLY;	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
CMU0975 A-IV-i-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 (CYCLES 1 AND 3 ONLY) - RITUXIMAB 375MG/M2 IV.	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
CMU0975 A-IV-i-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4); HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65500	65500	65500	65500	65500	65500	65500	65500
CMU0975 A-IV-i-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU0975 A-IV-i-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8	MEDICAL ONCOLOGY	14100	14100	14100	14100	14100	14100	14100	14100
CMU0975 A-IV-i-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
CMU0975 A-IV-i-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0975 A-IV-i-b-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS.	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
CMU0975 A-IV-i-c-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
CMU0975 A-IV-i-c-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES.	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CMU0975 A-IV-i-c-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY.	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CMU0975 A-IV-i-c-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CMU0975 A-IV-i-c-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CMU0975 A-IV-i-c-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CMU0975 A-IV-ii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-IV-ii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
CMU0975 A-IV-ii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65500	65500	65500	65500	65500	65500	65500	65500
CMU0975 A-IV-ii-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU0975 A-IV-ii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES	MEDICAL ONCOLOGY	14100	14100	14100	14100	14100	14100	14100	14100
CMU0975 A-IV-ii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
CMU0975 A-IV-ii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CMU0975 A-IV-ii-a-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS.	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
CMU0975 A-IV-ii-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	16400	16400	16400	16400	16400	16400	16400	16400
CMU0975 A-IV-ii-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES.	MEDICAL ONCOLOGY	12700	12700	12700	12700	12700	12700	12700	12700
CMU0975 A-IV-ii-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY.	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CMU0975 A-IV-ii-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CMU0975 A-IV-ii-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CMU0975 A-IV-ii-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CMU0975 A-IV-ii-c : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CORTICOSTEROIDS + TKIS - PRETREATMENT	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
CMU0975 A-IV-iii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-IV-iii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 INDUCTION - CORTICOSTEROID PRE-PHASE - 1-7 DAYS BEFORE INDUCTION THERAPY; PREDNISONE 60MG/M2/DAY, 4-7 DAYS BEFORE INDUCTION THERAPY; MTX 15MG IT. INDUCTION I - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2/DAY + VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 50MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY, DAY 8; VINCRISTINE 2MG IV + L-ASPARAGINASE 6, 000IU/M2/DAY, DAYS 10 AND 12; L-ASPARAGINASE 6, 000IU/M2/DAY, DAY 15; VINCRISTINE 2MG IV, DAY 15; FOR GOOD EARLY RESPONDERS; CYCLOPHOSPHAMIDE 750MG/M2/DAY.	MEDICAL ONCOLOGY	16500	16500	16500	16500	16500	16500	16500	16500
CMU0975 A-IV-iii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 SALVAGE - DAYS 1-3; IDARUBICIN 12MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY.	MEDICAL ONCOLOGY	30200	30200	30200	30200	30200	30200	30200	30200
CMU0975 A-IV-iii-a-3 : ALL - PH(-) AYA - GRAALL-2003 CONSOLIDATION - BLOCKS 1, 4, AND 7; - DAYS 1 AND 2; CYTARABINE 2G/M2/12 HOURS + DEXAMETHASONE 10MG/12 HOURS, DAY 3; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 7-13; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 2, 5, AND 8 - DAY 15; MTX 3G/M2 CONTINUOUS INFUSION + VINCRISTINE 2MG IV + 6-MP 60MG/M2/DAY, DAY 16; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 16-21; 6-MP 60MG/M2/DAY, DAYS 22-27; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 3, 6, AND 9 - DAY 29; MTX 25MG/M2/DAY, DAYS 29 AND 30; CYCLOPHOSPHAMIDE 500MG/M2/DAY + ETOPOSIDE 75MG/M2/DAY, DAY 31; FILGRASTIM TO MYELOID RECOVERY. TO BE APPROVED 3 TIMES (BLOCKS - 1, 2, 3; BLOCKS - 4, 5, 6; BLOCKS - 7, 8, 9	MEDICAL ONCOLOGY	32300	32300	32300	32300	32300	32300	32300	32300
CMU0975 A-IV-iii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN COMPLETE REMISSION [CR] AFTER THE FIRST INDUCTION COURSE) - DAY 1; VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 30MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY	MEDICAL ONCOLOGY	16300	16300	16300	16300	16300	16300	16300	16300
CMU0975 A-IV-iii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN CR AFTER SALVAGE COURSE) - DAYS 1-3; IDARUBICIN 9MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY.	MEDICAL ONCOLOGY	28600	28600	28600	28600	28600	28600	28600	28600
CMU0975 A-IV-iii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 MAINTENANCE	MEDICAL ONCOLOGY	59800	59800	59800	59800	59800	59800	59800	59800
CMU0975 A-IV-iii-b : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CNS THERAPY-TREATMENT OF PATIENTS WITH INITIAL CNS INVOLVEMENT	MEDICAL ONCOLOGY	22200	22200	22200	22200	22200	22200	22200	22200
CMU0975 A-IV-iii-v : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CCG-1961	MEDICAL ONCOLOGY	19200	19200	19200	19200	19200	19200	19200	19200
CMU0975 A-IV-iv : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0975 A-IV-iv-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) INDUCTION	MEDICAL ONCOLOGY	19000	19000	19000	19000	19000	19000	19000	19000
CMU0975 A-IV-iv-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) CONSOLIDATION	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
CMU0975 A-IV-iv-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 1, 3, 5, 7 - DAYS 1 - 3 - CYCLOPHOSPHAMIDE IV EVERY 12 HOURS + MESNA CONTINUOUS IV INFUSION STARTING 1 HOUR BEFORE CYCLOPHOSPHAMIDE UNTIL 12 HOURS AFTER COMPLETION OF CYCLOPHOSPHAMIDE; DAYS 1 - 4 AND 11 - 14 - DEXAMETHASONE ORALLY DAILY, +/-; DAYS 1 AND 8 - RITUXIMABIV; DAY 4 - DOXORUBICIN IV OVER 24 HOURS; DAYS 4 AND 11 - VINCRISTINE IV	MEDICAL ONCOLOGY	64000	64000	64000	64000	64000	64000	64000	64000
CMU0975 A-IV-iv-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 2, 4, 6, 8 - DAY 1 - METHOTREXATE IV OVER 2 HOURS FOLLOWED BY CONTINUOUS IV INFUSION OVER 22 HOURS FOLLOWED BY LEUCOVORIN IV EVERY 6 HOURS STARTING 12 HOURS AFTER COMPLETION OF MTX; DAYS 2 - 3 - CYTARABINE (IV OVER 2 HOURS EVERY 12 HOURS, +/-; DAYS 1 AND 8 - RITUXIMAB 375MG/M2 IV; CNS PROPHYLAXIS; DAY 2 - METHOTREXATE 12MG IT; DAY 8 - CYTARABINE 100MG IT.	MEDICAL ONCOLOGY	59700	59700	59700	59700	59700	59700	59700	59700
CMU0976 A : ALL LYMPHOMACHEMOTHERAPHY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0976 A-I : HODGKINS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU0976 A-I-a : HODGKINSLYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CMU0976 A-I-b : HODGKINSLYMPHOMA - ESCALATED BEACOPP - DAY 1; CYCLOPHOSPHAMIDE 1, 250MG/M2 IV OVER 60 MINUTES + DOXORUBICIN 35MG/M2 IV PUSH, DAYS 1-3; ETOPOSIDE 200MG/M2 IV OVER 2 HOURS	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU0976 A-I-c : HODGKINSLYMPHOMA - ABVD + RITUXIMAB (CYLED EVERY 4 WEEKS) -	MEDICAL ONCOLOGY	24300	24300	24300	24300	24300	24300	24300	24300
CMU0976 A-I-d-i : HODGKINS LYMPHOMA - ABVD + RITUXIMAB (1 CYCLE - WEEKLY RITUXIMAB 4 DOSES) FOLLOWED BY ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV FOR CYCLE 1 ONLY. REPEAT ABVD CYCLE EVERY 4 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION (OR ) 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION	MEDICAL ONCOLOGY	87200	87200	87200	87200	87200	87200	87200	87200
CMU0976 A-I-d-ii : HODGKINS LYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CMU0976 A-I-e-i : HODGKINS LYMPHOMA - CHOP + RITUXIMAB - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV, REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
CMU0976 A-I-e-ii : HODGKINS LYMPHOMA - CHOP - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CMU0976 A-I-f-i : HODGKINS LYMPHOMA - CVP +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22000	22000	22000	22000	22000	22000	22000	22000
CMU0976 A-I-f-ii : HODGKINS LYMPHOMA - CVP - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CMU0976 A-I-g : HODGKINSLYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 7 DAYS FOR 4 WEEKS WITH OR WITHOUT MAINTENANCE RITUXIMAB (375MG/M2 IV ONCE WEEKLY FOR 4 WEEKS EVERY 6 MONTHS FOR UP TO 2 YEARS)	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
CMU1259 : Bone marrow aspiration of biopsy	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CMU1296-I : CT for CA Breast -Weekly Paclitaxel for Adjuvant Therapy Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
CMU1296-II : CT for CA Breast - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CMU1296-III : CT for CA Breast - Capecitabine for triple negative with residual disease after pre op taxane , alkylator, antracyclin. Capecitabine - 1000mg/m2 orally twice daily D1-D14 every 21 days	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
CMU1296-IV : CT for CA Breast - Carboplatin + Gemcitabine for her2 negative, unresectable or stage 4 -M1 disease. Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1296-V : CT for CA Breast - Fulvestrant for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Fulvestrant 500 mg D1 D15 D28 then every 28 days. per dose13200 (39600 in cycle1 ) then 13200 per month - (per dose 45000 in cycle1 ) then 15000 per month	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU1296-VI : CT for CA Breast - Exemestane for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Exemestane 25 mg orally daily (q 3 monthsly)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CMU1296-VII : CT for CA Breast - Lapatinib for her2 positive, unresectable or stage 4 -M1 disease. Lapatinib 500 mg BD orally , daily	MEDICAL ONCOLOGY	15050	15050	15050	15050	15050	15050	15050	15050
CMU1297 : CT for Metastatic bone malignancy - Zoledronic Acid Zoledronic acid 4 mg IV Monthly	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CMU1298-I : CT for CA Ovary - Cisplatin + Irinotecan for Recurrent Platinum-Sensitive Epithelial cancer Cisplatin 60mg/m2 D1 Irinotecan 60 mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	13050	13050	13050	13050	13050	13050	13050	13050
CMU1298-II : CT for CA Ovary - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5-6 D1 every 28 days	MEDICAL ONCOLOGY	17200	17200	17200	17200	17200	17200	17200	17200
CMU1298-III : CT for CA Ovary - Etoposide for Recurrent Platinum-Resistant Epithelial Ovarian cancer Etoposide 50 mg/m2 OD D1-D21 every 28 days	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CMU1298-IV : CT for CA Ovary - Irinotecan Recurrent Epithelial Ovarian cancer Irinotecan 60 -90 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	10950	10950	10950	10950	10950	10950	10950	10950
CMU1298-IX : CT for CA Ovary - Letrozole Letrozole 2.5 mg orally daily (3 months)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CMU1298-V : CT for CA Ovary - Lipodox for Recurrent Platinum-Resistant Epithelial Ovarian cancer Lipodox 40 mg/m2 IV every 28 days	MEDICAL ONCOLOGY	17950	17950	17950	17950	17950	17950	17950	17950
CMU1298-VI : CT for CA Ovary - Carboplatin + Gemcitabine for Recurrent Platinum-Sensitive Epithelial Ovarian Cancer Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1298-VII : CT for CA Ovary - Cyclophosphamide for Recurrent Epithelial Ovarian Cancer Cyclophosphamide 50 mg/m2 OD D1-D21 every 28 days	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
CMU1298-VIII : CT for CA Ovary - Tamoxifen Tamoxifem 20 mg orally daily (3 months)	MEDICAL ONCOLOGY	1200	1200	1200	1200	1200	1200	1200	1200
CMU1298-X : CT for CA Ovary - Single agent Carboplatin Carboplatin AUC 5-6 D1 every 21 days ( maximum -6 cycle)	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
CMU1298-XI : CT for CA Ovary - Cisplatin Cisplatin 40 mg/m2 every week (maximum- 6 cycles)	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
CMU1299-I : CT for Germ Cell Tumor - Carboplatin (AUC 7) Carboplatin AUC 7 every 21 days	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
CMU1299-II : CT for Germ Cell Tumor - Etoposide + Cisplatin Cisplatin 20 mg/m2 IV D1-D5 Etoposide 100mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	10860	10860	10860	10860	10860	10860	10860	10860
CMU1299-III : CT for Germ Cell Tumor - Gemcitabine + Oxaliplatin Gemcitabine 1000mg/m2 D1 D8 Oxaiplatin 130mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
CMU1299-IV : CT for Germ Cell Tumor - Gemcitabine + Paclitaxel Gemcitabine 1000mg/m2 D1 D8 D15 Paclitaxel 100 mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
CMU1299-V : CT for Germ Cell Tumor - Paclitaxel + Ifosfamide + Cisplatin Paclitaxel 240 mg/m2 D1 Ifosfamide 1500mg/m2 D2-D5 Mesna 300 mg/m2 0h 4h 8h D2-D5 Cisplatin 25mg/m2 D2-D5 every 21 days	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
CMU1299-VI : CT for Germ Cell Tumor - Vinblastin + Ifosfamide + Cisplatin Vinblastine 0.11 mg/kg IV D1-D2 Mesna 240mg/m2 0h 4h 8h D1-D5 Ifosfamide 1200mg/m2 D1-D5 Cisplatin 20 mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	13600	13600	13600	13600	13600	13600	13600	13600
CMU1300 : CT for Gestational Trophoblastic Neoplasia - Etoposide + Methotrexate + Dactinomycin + Cisplatin Etoposide 100mg/m2 IV D1 D2 D8 Dactinomycin 0.5 mg IV push D1 D2 Methotrexate 300 mg /m2 D1 Leucovorin 15 mg PO every 12 hrs for 4 doses Cisplatin 75mg/m2 D8 every 2 weeks	MEDICAL ONCOLOGY	12750	12750	12750	12750	12750	12750	12750	12750
CMU1301 : CT for Cervical Cancer - Carboplatin + Paclitaxel (recurrent or metastatic) Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CMU1302-I : CT for Endometrial Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CMU1302-II : CT for Endometrial Cancer - Cisplatin + Doxorubicin Doxorubicin 60 mg/m2 D1 Cisplatin 50mg/m2 every 3 weeks	MEDICAL ONCOLOGY	4410	4410	4410	4410	4410	4410	4410	4410
CMU1302-III : CT for Endometrial Cancer - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5 D1 every 28 days	MEDICAL ONCOLOGY	17200	17200	17200	17200	17200	17200	17200	17200
CMU1302-IV : CT for Endometrial Cancer - Carboplatin + Gemcitabine Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only every 3 weeks	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1302-V : CT for Endometrial Cancer - Anastrozole 1 mg orally daily (for 3 months)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CMU1303 : CT for Vulvar Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1304-I : CT for Ewing Sarcoma - Vincristine + Topotecan + Cyclophosphamide + Irinotecan + Temozolamide Vincristine 1.5mg/m2( day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) Given every 3 weeks Irinotecan 10-50 mg/sqM days 1-5 and days 8-12 Temozolamide 100mg/m2 days 1-5 of each cycle every 3 weeks	MEDICAL ONCOLOGY	23160	23160	23160	23160	23160	23160	23160	23160
CMU1304-II : CT for Ewing Sarcoma - VIE 4 cycles + VAC 6 cycles + VCD 4 cycles; VIE - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (day 1, 8 and 15) Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 3 weeks	MEDICAL ONCOLOGY	9900	9900	9900	9900	9900	9900	9900	9900
CMU1304-III : CT for Ewing Sarcoma - Vincristine + Adriamycin + Cyclophosphamide Ifosfamide + Etoposide Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 2-3 weekly Vincristine 1.5mg/m2 (day 1 and 8) Adriamyicn: 75mg/m2 (day 1) Cyclophosphamide 1200mg/m2 (day 1) Given 2-3 weekly	MEDICAL ONCOLOGY	12710	12710	12710	12710	12710	12710	12710	12710
CMU1305-I : CT for Osteogenic Sarcoma - Doxorubicin + Cisplatin Cisplatin 100mg/m2 Doxorubicin 75mg/m2 given every 3 weeks	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CMU1305-II : CT for Osteogenic Sarcoma - Methotrexate + Doxorubicin + Cisplatin for Relapsed Osteogenic Sarcoma Cisplatin 120mg/sq.m Doxorubicin 75mg/m2 Methotrexate 8-12 gram/m2 Each cycle for 5 weeks	MEDICAL ONCOLOGY	27000	27000	27000	27000	27000	27000	27000	27000
CMU1305-III : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Adriamycin 25mg/m2 D1- D3 Cisplatin 33 mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	29600	29600	29600	29600	29600	29600	29600	29600
CMU1305-IV : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Cisplatin 33 mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	28600	28600	28600	28600	28600	28600	28600	28600
CMU1306 : CT for Soft Tissue Sarcoma - Ifosfamide + Adriamycin Doxorubicin 30mg/m2 D1 D2 Ifosfamide 2000 to 3000mg/m2 Mesna 400 to 600 mg/m2 0h 4h 8h D1 - D3 Every 21 days	MEDICAL ONCOLOGY	13700	13700	13700	13700	13700	13700	13700	13700
CMU1307-I : CT for Metastatic Melanoma - Dacarbazine + Cisplatin Dacarbazine 250mg/m2 D1-D5 Cisplatin 75 mg/m2 Every 21 days	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CMU1307-II : CT for Metastatic Melanoma - Temozolamide Temozolamide 200mg/m2 D1-D5 every 28 days	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CMU1307-III : CT for Metastatic Melanoma - Imatinib Tab Imatinib 400/800 mg daily	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CMU1308-I : CT for Anal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CMU1308-II : CT for Anal Cancer - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
CMU1309-I : CT for Colorectal Cancer - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CMU1309-II : CT for Colorectal Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9570	9570	9570	9570	9570	9570	9570	9570
CMU1309-III : CT for Colorectal Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days	MEDICAL ONCOLOGY	18780	18780	18780	18780	18780	18780	18780	18780
CMU1310 : CT for Esophageal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CMU1311-I : CT for Esophageal / Stomach Cancer - Irinotecan Irinotecan 60- 90 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	10930	10930	10930	10930	10930	10930	10930	10930
CMU1311-II : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + 5 FU Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1000mg/m2 D1 D2 every 14 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1311-III : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + Capecitabine Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Capecitabine 825mg/m2 twice daily every 14 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1311-IV : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + 5 FU Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1200mg/m2 D1 D2 every 14 days	MEDICAL ONCOLOGY	18500	18500	18500	18500	18500	18500	18500	18500
CMU1311-V : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + Capecitabine Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Capecitabine 825 mg/m2 Twice daily every 14 days	MEDICAL ONCOLOGY	18500	18500	18500	18500	18500	18500	18500	18500
CMU1311-VI : CT for Esophageal / Stomach Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9570	9570	9570	9570	9570	9570	9570	9570
CMU1311-VII : CT for Esophageal / Stomach Cancer - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5990	5990	5990	5990	5990	5990	5990	5990
CMU1312-I : CT for Hepatocellular Carcinoma - Doxorubicin (TACE) Doxorubicin 30-75 mg/m2 one course	MEDICAL ONCOLOGY	22500	22500	22500	22500	22500	22500	22500	22500
CMU1312-II : CT for Hepatocellular Carcinoma - Lenvatinib 12 mg daily	MEDICAL ONCOLOGY	17000	17000	17000	17000	17000	17000	17000	17000
CMU1313-I : CT for Panceratic Cancer - Gemcitabine + Nanopaclitaxel Gemcitabine 1000mg/m2 D1 D8 D16 Albumin bound Paclitaxel 125mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	28380	28380	28380	28380	28380	28380	28380	28380
CMU1313-II : CT for Panceratic Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days	MEDICAL ONCOLOGY	18880	18880	18880	18880	18880	18880	18880	18880
CMU1313-III : CT for Panceratic Cancer - Capecitabine + Gemcitabine Gemcitabine 1000mg/m2 D1 D8 D15 Capecitabine 830mg/m2 twice daily D1-D21 every 28 days	MEDICAL ONCOLOGY	34130	34130	34130	34130	34130	34130	34130	34130
CMU1314-I : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9620	9620	9620	9620	9620	9620	9620	9620
CMU1314-II : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 300 mg/m2 D 1(weekly till RT ends)	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU1314-III : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	8980	8980	8980	8980	8980	8980	8980	8980
CMU1314-IV : CT for Gall Bladder Cancer / Cholangiocarcinoma - Oxaliplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 Oxaliplatin 100 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	17400	17400	17400	17400	17400	17400	17400	17400
CMU1314-V : CT for Gall Bladder Cancer / Cholangiocarcinoma - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CMU1314-VI : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Oxaliplatin 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	13700	13700	13700	13700	13700	13700	13700	13700
CMU1315 : CT for Gastointestinal stromal tumor - Sunitinib Sunitinb 37.5 mg once daily	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CMU1316 : CT for Mesothelioma - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
CMU1317 : CT for Thymic Carcinoma - Cisplatin + Etoposide Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CMU1318-I : CT for CA Head & Neck - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1318-II : CT for CA Head & Neck - Docetaxel Docetaxel 20mg/m2 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU1318-III : CT for CA Head & Neck - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CMU1318-IV : CT for CA Head & Neck - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	7690	7690	7690	7690	7690	7690	7690	7690
CMU1318-IX : CT for CA Head & Neck - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5970	5970	5970	5970	5970	5970	5970	5970
CMU1318-V : CT for CA Head & Neck - Etoposide + Cisplatin Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	9270	9270	9270	9270	9270	9270	9270	9270
CMU1318-VI : CT for CA Head & Neck - Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
CMU1318-VII : CT for CA Head & Neck - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
CMU1318-VIII : CT for CA Head & Neck - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1318-X : CT for CA Head & Neck - Paclitaxel Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	11800	11800	11800	11800	11800	11800	11800	11800
CMU1318-XI : CT for CA Head & Neck - Carboplatin Carboplatin AUC 2 every week	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CMU1319 : CT for Renal Cell Cancer - Cabozantinib 60 mg od x 1 month every 4 weeks	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
CMU1320-I : CT for Ureter / Urethra - Cisplatin + Methotrexate + Vinblastin Methotrexate 30mg/m2 D1 D8 Vinblastine 4 mg/m2 D1 D8 Doxorubicin 30 mg/m2 D2 Cisplatin 100 mg/m2 D2 Leucovorin 15 mg PO D2 D9 every 21 days	MEDICAL ONCOLOGY	6750	6750	6750	6750	6750	6750	6750	6750
CMU1320-II : CT for Ureter / Bladder / Urethra - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1320-III : CT for Ureter / Urethra - Cisplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
CMU1320-IV : CT for Ureter / Urethra - Cisplatin + 5 FU 5 FU 1000mg/m2 D1-D4 Cisplatin 75mg/m2 D1 every 4 weeks	MEDICAL ONCOLOGY	8180	8180	8180	8180	8180	8180	8180	8180
CMU1320-IX : CT for Ureter / Urethra - Methotrexate + Vinblastin + Doxorubicin + Cisplatin Methotrexate 30mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicin 30 mg/m2 D2 Cuisplatin 70 mg/m2 D2 every 14 days	MEDICAL ONCOLOGY	7540	7540	7540	7540	7540	7540	7540	7540
CMU1320-V : CT for Ureter / Bladder / Urethra - Cisplatin + Paclitaxel Paclitaxel 175 mg /m2 D1 Cisplatin 75 mg /m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
CMU1320-VI : CT for Ureter / Bladder / Urethra - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CMU1320-VII : CT for Ureter / Bladder / Urethra - Gemcitabine + Paclitaxel Gemcitabine 2500 mg/m2 D1 Paclitaxel 150 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	15500	15500	15500	15500	15500	15500	15500	15500
CMU1320-VIII : CT for Ureter / Bladder / Urethra - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
CMU1320-X : CT for Ureter / Bladder / Urethra - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1320-XI : CT for Ureter / Urethra - Paclitaxel Paclitaxel 80 mg/m2 D1 every week	MEDICAL ONCOLOGY	6380	6380	6380	6380	6380	6380	6380	6380
CMU1321-I : CT for CA Penis - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
CMU1321-II : CT for CA Penis - Capecitabine Capecitabine 1000-1250 mg/m2 PO twice daily D1 -D14 every 21 days	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
CMU1321-III : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1321-IV : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 80 mg/m2 D1 Carboplatin AUC 2 D1 every week	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
CMU1322-I : CT for CA Prostate - Docetaxel Docetaxel 60 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU1322-II : CT for CA Prostate - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	7690	7690	7690	7690	7690	7690	7690	7690
CMU1322-III : CT for CA Prostate - LHRH Agonist Leuprolide 22.5 ug every 3 months	MEDICAL ONCOLOGY	15300	15300	15300	15300	15300	15300	15300	15300
CMU1322-IV : CT for CA Prostate - Mitoxantrone + Prednisolone Mitoxantrone 12mg/m2 every 3 weeks Prednsiolone 10 mg daily	MEDICAL ONCOLOGY	4200	4200	4200	4200	4200	4200	4200	4200
CMU1322-V : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 80mg/m2 D1 Carboplatin AUC 2 D1 every week	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
CMU1322-VI : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CMU1322-VII : CT for CA Prostate - Docetaxel Docetaxel 20mg/m2 D1 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU1322-VIII : CT for CA Prostate - Abiraterone 1000 mg + Prednisolone 10mg daily Once every month	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
CMU1343A : CT for Low Grade Glioma - Vincristine + Carboplatin Vincristine 1.5mg/m2 (day 1, 8 and 15 for first 4 cycles and then only day 1 from cycle 5 to 17) Carboplatin 550mg/m2 every 3 weeks (all cycles)	MEDICAL ONCOLOGY	5850	5850	5850	5850	5850	5850	5850	5850
CMU1343B : CT for Low Grade Glioma - Vinblastin Vinblastine 6 mg/m2 every week	MEDICAL ONCOLOGY	3340	3340	3340	3340	3340	3340	3340	3340
CMU1344A : CT for Neuroblastoma - Cabroplatin + Etoposide + Cyclophosphamide + Doxorubicin Carboplatin 600mg/m2 Etoposide 100mg/m2 (days 1-5) Cyclophosphamide Doxorubicin	MEDICAL ONCOLOGY	8590	8590	8590	8590	8590	8590	8590	8590
CMU1344C : CT for Neuroblastoma - 13-cis retinoic acid 160mg/m2 per day for 2 weeks Each cycle given 4 weekly	MEDICAL ONCOLOGY	2030	2030	2030	2030	2030	2030	2030	2030
CMU1345B : CT for Rhabdomyosarcoma - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (days 1, 8 and 15) Ifosfamide 1.8gm/m2 (days 1-5) Etoposide 100mg/m2 (days 1-5) Each cycle every 3 weeks	MEDICAL ONCOLOGY	16200	16200	16200	16200	16200	16200	16200	16200
CMU1346A : CT for Relapse Rhabdomyosarcoma - Vincristine + Topotecan + Cyclophosphamide and Vincristine + Adriamycin + Cyclophosphamide Vincristine 1.5mg/m2 (day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) 3 - weekly Vincristine 1.5mg/m2 Adriamyicn 60mg/m2 Cyclophosphamide 600mg/m2 (all Day 1) Every 3 weeks. Cycles given in couplets	MEDICAL ONCOLOGY	12420	12420	12420	12420	12420	12420	12420	12420
CMU1347A : CT for Pediatric Acute Lymphoblastic Leukemia - Consolidation (Phase II, CNS Therapy Reinduction)	MEDICAL ONCOLOGY	239650	239650	239650	239650	239650	239650	239650	239650
CMU1347B-I : CT for Pediatric Acute Lymphoblastic Leukemia - ICICLE	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1347B-II : CT for Pediatric Acute Lymphoblastic Leukemia - BFM	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1347B-III : CT for Pediatric Acute Lymphoblastic Leukemia KLALL	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1347B-IV : CT for Pediatric Acute Lymphoblastic Leukemia - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1347C : CT for Pediatric Acute Lymphoblastic Leukemia - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly	MEDICAL ONCOLOGY	2670	2670	2670	2670	2670	2670	2670	2670
CMU1347D : CT for Ph+ve Pediatric Acute Lymphoblastic Leukemia for adult and paediatric - Dasatinib + chemo (to be used only with ALL therapy)	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CMU1348A : CT for Pediatric Lymphoblastic Lymphoma - Consolidation (Phase II, CNS Therapy Reinduction)	MEDICAL ONCOLOGY	239650	239650	239650	239650	239650	239650	239650	239650
CMU1348B-I : CT for Pediatric Lymphoblastic Lymphoma - ICICLE	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1348B-II : CT for Pediatric Lymphoblastic Lymphoma -BFM	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1348B-III : CT for Pediatric Lymphoblastic Lymphoma - KLALL	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1348B-IV : CT for Pediatric Lymphoblastic Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
CMU1348C : CT for Pediatric Lymphoblastic Lymphoma - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly	MEDICAL ONCOLOGY	2670	2670	2670	2670	2670	2670	2670	2670
CMU1349B : CT for Pediatric Acute Myeloid Leukemia - Cytrabine 200mg/m2/day days 1-10 and Daunorubicin 50mg/m2 days 1, 3 and 5 Etposide 100mg/m2 days 1-5	MEDICAL ONCOLOGY	105240	105240	105240	105240	105240	105240	105240	105240
CMU1350A : CT for Pediatric Acute Promyelocytic Leukemia - Consolidation	MEDICAL ONCOLOGY	58800	58800	58800	58800	58800	58800	58800	58800
CMU1350B : CT for Pediatric Acute Promyelocytic Leukemia - Induction	MEDICAL ONCOLOGY	129400	129400	129400	129400	129400	129400	129400	129400
CMU1350C : CT for Pediatric Acute Promyelocytic Leukemia - Maintenance (18 months total cost)	MEDICAL ONCOLOGY	39300	39300	39300	39300	39300	39300	39300	39300
CMU1351A : CT for Pediatric Hodgkins Lymphoma - COPDAC - Cyclophosphamide, Vincristine sulfate,Prednisone,Dacarbazine	MEDICAL ONCOLOGY	9450	9450	9450	9450	9450	9450	9450	9450
CMU1351B : CT for Pediatric Hodgkins Lymphoma - OPEA - Oncovin,Etoposide,Prednisone,doxorubicin hydrochloride	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
CMU1352A : CT for Pediatric Hodgkins Lymphoma Relapse - ICE - ifosfamide, carboplatin, etoposide	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
CMU1352B : CT for Pediatric Hodgkins Lymphoma Relapse - DECA - Dexamethasone, Etoposide, Cytarabine, Cisplatin	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
CMU1352C : CT for Pediatric Hodgkins Lymphoma Relapse - IGVD	MEDICAL ONCOLOGY	34000	34000	34000	34000	34000	34000	34000	34000
CMU1353A : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (second month)	MEDICAL ONCOLOGY	42570	42570	42570	42570	42570	42570	42570	42570
CMU1353B : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (first month)	MEDICAL ONCOLOGY	42420	42420	42420	42420	42420	42420	42420	42420
CMU1353C : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Maintenance	MEDICAL ONCOLOGY	65780	65780	65780	65780	65780	65780	65780	65780
CMU1353D : CT for Pediatric Non Hodgkins Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 842	MEDICAL ONCOLOGY	98700	98700	98700	98700	98700	98700	98700	98700
CMU1354A : Pediatric - Germ Cell Tumor / JEB	MEDICAL ONCOLOGY	10650	10650	10650	10650	10650	10650	10650	10650
CMU1355A : CT for Pediatric Hepatoblastoma - Carboplatin + Cisplatin + Doxorubicin	MEDICAL ONCOLOGY	5590	5590	5590	5590	5590	5590	5590	5590
CMU1355B : CT for Pediatric Hepatoblastoma - Cisplatin	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CMU1356A : CT for CA Lung - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CMU1356B : CT for CA Lung - Erlotinib Erlotinib 150 mg once daily	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
CMU1356C : CT for CA Lung - Gefitnib Gefitinib 250 mg once daily	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CMU1356F : CT for CA Lung - Topotecan Topotecan 1.5 mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	24600	24600	24600	24600	24600	24600	24600	24600
CMU1356G : CT for CA Lung - Docetaxel Docetaxel 20 mg/m2 D1 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CMU1356J : CT for CA Lung - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	8980	8980	8980	8980	8980	8980	8980	8980
CMU1356K : CT for CA Lung - Gemcitabine + Carboplatin Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
CMU1356M : CT for CA Lung - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5990	5990	5990	5990	5990	5990	5990	5990
CMU1356N : CT for CA Lung - Paclitaxel Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	11800	11800	11800	11800	11800	11800	11800	11800
CMU1356P : CT for CA Lung - Paclitaxel + Cisplatin Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
CMU1356S : CT for CA Lung - Vinorelbine + Carboplatin Vinorelbine 25mg/m2 D1 D8 CarboplatinAUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	17000	17000	17000	17000	17000	17000	17000	17000
CMU1357A : CT for CA Cervix - Carboplatin Carboplatin AUC 2 every week	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CMU1358A : CT for primary CNS lymphoma - De-Angelis/MTR	MEDICAL ONCOLOGY	36000	36000	36000	36000	36000	36000	36000	36000
CMU1359A : GCT Testis - SA Carboplatin AUC 7 once every 3 weeks	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CMU1360A : CT for GCT of bone - Denosumab Denosumab 120 mg s/c D1, 8, 15 then every 28 days - 19800 per dose. Max 6 dose	MEDICAL ONCOLOGY	18000	18000	18000	18000	18000	18000	18000	18000
CMU1361A : GEP NET Neuroendocrine carcinoma - Temozolamide 150mg/m2 D9-14 + Capecitabine 1gm/me D1-14 every 28 days	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CMU1361B : GEP NET high grade Neuroendocrine carcinoma - Carboplatin AUC 5 + Etoposide 100mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	13400	13400	13400	13400	13400	13400	13400	13400
CMU1424A : Central lines in cancer patients for drug therapy -Silicon catheters in advanced cancer patients- Long term central lines	MEDICAL ONCOLOGY	10000	0	0	0	0	0	0	0